



Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process

Amin Karimi-Moghadam¹ · Saeid Charsouei² · Benjamin Bell³ · Mohammad Reza Jabalameli^{1,3}

Received: 12 February 2018 / Accepted: 20 April 2018 / Published online: 26 April 2018
© The Author(s) 2018

Abstract

Parkinson disease (PD) is known as a common progressive neurodegenerative disease which is clinically diagnosed by the manifestation of numerous motor and nonmotor symptoms. PD is a genetically heterogeneous disorder with both familial and sporadic forms. To date, researches in the field of Parkinsonism have identified 23 genes or loci linked to rare monogenic familial forms of PD with Mendelian inheritance. Biochemical studies revealed that the products of these genes usually play key roles in the proper protein and mitochondrial quality control processes, as well as synaptic transmission and vesicular recycling pathways within neurons. Despite this, large number of patients affected with PD typically tends to show sporadic forms of disease with lack of a clear family history. Recent genome-wide association studies (GWAS) meta-analyses on the large sporadic PD case–control samples from European populations have identified over 12 genetic risk factors. However, the genetic etiology that underlies pathogenesis of PD is also discussed, since it remains unidentified in 40% of all PD-affected cases. Nowadays, with the emergence of new genetic techniques, international PD genomics consortiums and public online resources such as PDGene, there are many hopes that future large-scale genetics projects provide further insights into the genetic etiology of PD and improve diagnostic accuracy and therapeutic clinical trial designs.

Keywords Parkinson disease · Neurodegeneration · Autophagy · Mitochondrial dysfunction · Oxidative stress · GWAS meta-analysis

Introduction

Parkinson's disease (PD) was first described by James Parkinson, an English doctor, in 1817 (Kempster et al. 2007). PD is known as a chronic, progressive neurodegenerative disease that affects 2% of the population over the age of 60 and 4% of the population over the age of 80 (late-onset PD). However, 10% of the disease can occur in younger adults, between 20 and 50 years of age (early-onset PD). Besides the age, several studies have found evidence of gender influence in the incidence of PD. It has been proven that PD

is more prevalent in men than in women, with a ratio of 3:1, respectively; which may be attributable to the effect of estrogen on dopaminergic neurons and pathways in the brain (Schrag et al. 2000). PD is classically diagnosed by the manifestation of impaired motor function with an asymmetric onset that spreads with time to become bilateral. The majority motor impairments of PD arise owing to the dopaminergic neural loss in the substantia nigra pars compacta and the subsequent loss of dopamine input to forebrain (striatal) motor structures, leading to debilitating problems with tremor, muscular rigidity, and bradykinesia (slowness of movement) (Jankovic 2008). However, recent studies have recognized PD as a more complex disorder encompassing both motor (MS) and nonmotor symptoms (NMS). It has been proven that the occurrence of NMS is more prevalent among patients with PD and the frequency of them increases with the disease severity or during the course of the disease. Most patients with the long-term disease or severe pathology show 6–10 NMS. Also, there is increasing evidence that NMS such as sensory abnormalities (olfactory deficits), sleep disturbance (rapid eye movement), depression,

✉ Mohammad Reza Jabalameli
mjaf1d14@soton.ac.uk

¹ Division of Genetics, Department of Biology, Faculty of Science, University of Isfahan, Isfahan, Iran

² Department of Neurology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

³ Human Genetics & Genomic Medicine, Faculty of Medicine, Southampton General Hospital, University of Southampton, Southampton, UK

autonomic dysfunction, and cognitive decline may precede the onset of motor signs of Parkinson's disease (Jankovic 2008; O'sullivan et al. 2008). Therefore, NMS or premotor symptoms of the disease would be very informative for early diagnosis and identification of apparently normal older individuals with the full constellation of premotor signs and introducing neuroprotective strategies at an early stage in order to develop effective treatments for the disease (Berg et al. 2012; Stern et al. 2012).

Originally, PD has been identified as a genetically heterogeneous disorder which is classified into two genetic subtypes including monogenic familial forms with Mendelian inheritance and sporadic forms with no or less obvious familial aggregation. It has been proven that monogenic familial forms are caused by rare, highly penetrant pathogenic mutations; however, sporadic forms may result from contributions of environmental factors and genetic susceptibility (Davie 2008; De Lau and Breteler 2006; Lesage and Brice 2009; Taccioli et al. 2011). Now, considering the availability of high-throughput genetic analysis techniques and the access to large patient samples such as the International PD Genomics Consortium (IPDGC), the amount of information in the field of PD genetics in both areas is quickly growing. The aim of this review is to provide an overview of the recent genetic findings in both areas of familial and sporadic forms of PD disease.

Familial PD

Researches in the field of Parkinsonism have reported that approximately 10% of all PD-affected cases typically tend to show a clear Mendelian inheritance pattern and familial aggregation associated with the high risk of PD recurrence (Hardy et al. 2009). Over the past decades, through the genetic studies in these families, at least 23 disease-segregating genes or loci causing various monogenic forms of PD have been identified so far (Table 1). The knowledge acquired from the protein products of these genes indicates that mitochondrial dysfunctions and impaired autophagy-based protein or organelle degradation pathways all play key roles in the neurodegeneration process within brain and pathogenesis of PD (Mullin and Schapira 2013; Ryan et al. 2015). Here, the genes implicated in Mendelian forms of PD are reviewed.

SNCA

Synuclein-Alpha (*SNCA*) was the first PD-associated gene to be identified and is inherited in an autosomal dominant manner (Polymeropoulos et al. 1996). Patients affected with *SNCA* mutations exhibit clinically late-onset and typical

features of PD. However, several mutations have been identified to be associated with early-onset PD phenotypes and more severe features, including rapid progression of bradykinesia, rigidity and tremor, high prevalence of psychiatric symptoms, frequent dementia, prominent cognitive decline, autonomic dysfunctions, and moderate response to levodopa (L-3,4-dihydroxyphenylalanine; L-DOPA), which is a dopamine receptor agonist (Ibáñez et al. 2009; Lesage et al. 2013; Polymeropoulos et al. 1997). *SNCA* encodes a presynaptic protein (α -synuclein) and plays an important role in synaptic transmission (Liu et al. 2004). Several *in vivo* gene expression analyses have provided evidence for *SNCA* positive effects on synaptic vesicle recycling and mobilization in the proximity of axon terminal by its involvement in the regulation of phospholipase *D2* activity and induction of lipid droplet accumulation (Lotharius and Brundin 2002). Consistent with these analyses, some related experiments on animal models demonstrated that *SNCA* is associated with the synaptic plasticity by enhancing neurotransmitter release from the axon terminal (Nemani et al. 2010). In addition, several other studies have indicated the possible negative regulatory effect of *SNCA* on tyrosine hydroxylase activity, a rate-limiting enzyme in dopamine biosynthesis (Yu et al. 2004).

As illustrated in Table 1, to date, three classes of pathogenic mutations have been identified in *SNCA* gene: (1) missense point mutations in the coding region of *SNCA*, (2) dinucleotide repeat variation in the promoter region of *SNCA*, and (3) locus multiplications, including duplications and triplications, resulted from intra-allelic or inter-allelic unequal crossing over between Alu and LINE elements for segmental duplication, and both mechanisms for *SNCA* triplication. Quantitative gene expression analyses have proven that two last classes lead to pathogenic overexpression of the wild-type protein (Kojovic et al. 2012; Mutez et al. 2011).

SNCA mutations are suspected to have specific toxic effects in dopaminergic neurons. It seems that mutations in *SNCA* reduce the affinity of α -synuclein for lipids, thus increasing the tendency of the protein to form oligomers through a concentration-dependent mood, and consequently accelerate the formation of toxic α -synuclein fibrils (the major component of Lewy bodies) (Winner et al. 2011). It has been demonstrated that wild-type α -synuclein physically interacts with lysosome-associated membrane protein 2A (LAMP-2A), a transmembrane receptor for selective translocation of proteins into isolated lysosomes for the chaperone-mediated autophagy (CMA) pathway, providing support for the idea that CMA is involved in α -synuclein clearance (Fig. 1a). In fact, some pathogenic mutations in α -synuclein increase their affinity for LAMP-2A and act as uptake blockers, inhibiting both their own autophagy-dependent clearance and that of other CMA substrates. These studies provide another potential clue to the correlation of toxic

Table 1 Common familial Parkinson disease-associated genes and loci

| Loci | Inheritance | Gene | Position | Protein | Disease onset | Mutations |
|--------|------------------------|------------------|-----------|---|-------------------------------|---|
| PARK1 | AD rarely sporadic | <i>SNCA</i> | 4q21 | Synuclein-alpha | Early onset rarely late onset | Missense; regulatory gene duplication or triplication |
| PARK2 | AR sporadic | <i>PARKIN</i> | 6q25–q27 | E3 ubiquitin ligase | Early onset | Missense or nonsense; regulatory; splicing; small indels; deletions; insertions |
| PARK3 | AD | Unknown | 2p13 | Unknown | Late onset | Unknown |
| PARK4 | AD rarely sporadic | <i>SNCA</i> | 4q21 | Synuclein-alpha | Early onset rarely late onset | Missense; regulatory gene duplication or triplication |
| PARK5 | AD | <i>UCHL1</i> | 4p14 | Ubiquitin C-terminal hydrolase L1 | Late onset | Missense |
| PARK6 | AR | <i>PINK1</i> | 1p35–p36 | PTEN-induced kinase | Early onset | Missense or nonsense; splicing; small indels; deletions; insertions |
| PARK7 | AR | <i>DJ-1</i> | 1p36 | DJ-1 | Early onset | Missense; regulatory; splicing; small indels; deletions; insertions |
| PARK8 | AD sporadic | <i>LRRK2</i> | 12q12 | Leucine-rich repeat kinase 2 | Late onset | Missense; splicing; small deletions |
| PARK9 | AR | <i>ATP13A2</i> | 1p36 | Cation-transporting ATPase 13A2 | Early onset | Missense; splicing; small indels; deletions; insertions |
| PARK10 | Unclear | Unknown | 1p32 | Unknown | Unclear | Unknown |
| PARK11 | AD | <i>GIGYF2</i> | 2q36–q37 | GRB10 interacting GYF protein 2 | Late onset | Missense; small indels |
| PARK12 | Unclear | Unknown | Xq21–q25 | Unknown | Unclear | Unknown |
| PARK13 | AD | <i>Omi/HTRA2</i> | 2p13 | Serine peptidase 2 | Late onset | Missense; splicing |
| PARK14 | AR | <i>PLA2G6</i> | 22q12–q13 | Phospholipase A2, group 6 | Early onset | Missense; splicing; deletions; insertions |
| PARK15 | AR | <i>FBXO7</i> | 22q12–q13 | F-box protein 7 | Early onset | Missense; splicing |
| PARK17 | AD | <i>VPS35</i> | 16q11.2 | Vacuolar protein sorting 35 | Late onset | Missense; splicing |
| PARK18 | AD | <i>EIF4G1</i> | 3q27.1 | Eukaryotic translation initiation factor 4 gamma, 1 | Late onset | Missense; deletions; insertions |
| PARK19 | AR | <i>DNAJC6</i> | 1p31.3 | DNAJ subfamily C member 6 | Early onset | Missense or nonsense; splicing |
| PARK20 | AR | <i>SYNJ1</i> | 21q22.11 | Synaptojanin-1 | Early onset | Missense |
| PARK21 | AD | <i>DNAJC13</i> | 3q22.1 | DNAJ subfamily C member 13 | Early onset | Missense |
| PARK22 | AD | <i>CHCHD2</i> | 7p11.2 | Coiled-coil-helix-coiled-coil-helix domain 2 | Late onset | Missense |
| PARK23 | AR | <i>VPS13C</i> | 15q22.2 | Vacuolar protein sorting 13C | Early onset | Missense; small deletion |
| – | AD for PD AR for GD | <i>GBA</i> | 1q21 | Glucocerebrosidase | Unclear | Missense; regulatory; splicing; small indels; deletions; insertions |
| – | AD | <i>SCA2</i> | 12q24.1 | Spinocerebellar ataxia type 2 | Unclear | (CAG) three nucleotide repeat variations |

gain of function mutations in α -synuclein with the lesions in PD (Cuervo et al. 2004; Wang and Mao 2014; Xilouri et al. 2016). Also, there is a hypothesis that a deficit in

neurotransmitter release due to α -synuclein mutation could lead to cytoplasmic accumulation of dopamine, and increase oxidative stress and metabolic dysfunction in dopaminergic




Fig. 1 Lysosome-dependent degradation pathways; As indicated, **a** toxic α -synuclein aggregates are selectively degraded within the lysosome by means of LAMP-2A and chaperones; **b** GBA catalyzes the breakdown of sphingolipid glucosylceramide to ceramide and glucose within the lysosome; **c** damaged mitochondria is preferentially

degraded by autophagosomal membrane engulfment and subsequent fusion with lysosome; **d** ATP13A2 is located inside the lysosomal membrane and its proper function is essential to the lysosomal membrane stability

neurons (Lotharius and Brundin 2002), resulting from increased nonenzymatic and enzymatic oxidation of dopamine (Stefanis 2012). This finding has been corroborated by the Petrucelli et al. (2002) observations that mutant α -synuclein was selectively toxic to tyrosine hydroxylase positive neuroblastoma cells, but not in the neurons lacking tyrosine hydroxylase (Petrucelli et al. 2002).

PARKIN

The second type of PD is caused by mutations in the *PARKIN* gene which leads to the autosomal recessive juvenile Parkinsonism (ARJP), the most prevalent known cause of early-onset (before age 45 years) PD (49% of familial early-onset PD and 15% of sporadic early-onset PD). Lücking et al. (2000) elucidated that there is a significant decline in the frequency of *PARKIN* mutations with increasing age at PD onset (Lücking et al. 2000). In particular, PD onset occurs before the age of 20, in 80% of patients with homozygous or compound heterozygous mutations in *PARKIN* gene (Klein et al. 2003; Mata et al. 2004; Periquet et al. 2003). It is now evident that mutations in *PARKIN* are associated with early development of motor symptoms, hyperreflexia, bradykinesia, dystonia, tremor, good response to low dose of L-DOPA at onset, and later L-DOPA-induced dyskinesia, as well as slow progression of psychiatric symptoms,

with any clinical evidence of dementia (Ishikawa and Tsuji 1996; Ebba; Lohmann et al. 2003, 2009). Functionally, PARKIN is considered as a member of a multiprotein E3 ubiquitin ligase complex required for covalent attachment of activated ubiquitin molecules to target substrates (Shimura et al. 2000). This process is performed by a reaction cascade consisting of three groups of enzymes, including E1 ubiquitin-activating enzyme (UbA1), E2 ubiquitin-conjugating enzymes (UbCH7), and PARKIN E3 ubiquitin ligase (Pao et al. 2016; Trempe et al. 2013). The PARKIN-mediated ubiquitylation has various functional consequences, including the proteasomal degradation of misfolded or damaged proteins (Tanaka et al. 2004). It now appears that PARKIN also controls the mitochondrial quality through the selective lysosome-dependent degradation (autophagy or mitophagy) of dysfunctional mitochondria (Ryan et al. 2015).

As illustrated in Table 1, different types of mutations have been identified within *PARKIN* gene. Interestingly, it has proven that most of *PARKIN* mutation carriers have exon rearrangements in the heterozygous state (Stenson et al. 2017).

Mutations in *PARKIN* gene are associated with significant degeneration of dopaminergic neurons in the substantia nigra (Hristova et al. 2009). The presence of protein inclusions in Lewy bodies in PD patients led to the hypothesize that mutations in *PARKIN* cause a disruption in the E3

ubiquitin ligase activity of PARKIN, leading to insufficient clearance of damaged or mutated substrates and subsequent toxic cellular aggregation of unwanted proteins and neuronal cell death (Shimura et al. 2000). In addition, there is an idea that mutations in the *PARKIN* gene affect another important role of PARKIN in the turnover of mitochondria, reducing the ability of cells to remove damaged mitochondria by autophagy or mitophagy pathway (Pickrell and Youle 2015).

PINK1

Homozygous or compound heterozygous mutations in *PTEN-induced kinase (PINK1)* gene are considered as the second leading cause of recessive early-onset PD (Valente et al. 2004). Clinically, patients with mutations in *PINK1* tend to present symptoms before the age of 40 and longer mean disease durations (Ibáñez et al. 2006). It has been described that the frequency of mutations varies between different populations from 1 to 15% (Nuytemans et al. 2010). Also, it has been proven that the clinical phenotype of PD appears to be broadly similar between patients with *PARKIN* and *PINK1* mutations, suggesting the idea that they might act together in pathways relevant to PD pathogenesis (Ibáñez et al. 2006). Interestingly, studies in *Drosophila* and mice also indicated a common PINK1/PARKIN pathway important for maintaining mitochondrial fidelity (Burman et al. 2012; Damiano et al. 2014; Moiso et al. 2014; Park et al. 2006). Moreover, there are some indications that *PINK1* gene encodes a mitochondrial serine/threonine protein kinase and plays several important roles in mitochondrial pathways, including mitophagy, mitochondrial trafficking, and mitochondrial dynamics (Itoh et al. 2013; Narendra et al. 2010; Xinnan; Wang et al. 2011), which are largely consistent with the previous notion of PINK1/PARKIN common function in mitochondrial pathways.

Some mutations in *PINK1* may decrease the stability of the protein, whereas others significantly reduce the phosphorylation or kinase activity, supporting the hypothesis that mitochondrial dysfunction and oxidative stress may be associated with the PD (Deas et al. 2009; Gautier et al. 2008).

PINK1, PARKIN, and Mitochondrial Hemostasis

Selective autophagic degradation of damaged mitochondria is necessary for mitochondrial homeostasis, an essential process for the cell survival (Franco-Iborra et al. 2016; McLelland et al. 2014). Cell biology studies revealed that PARKIN is selectively activated and recruited to depolarized mitochondria in order to drive damaged mitochondrial degradation (Vives-Bauza et al. 2010). PINK1 detects bioenergetically defective mitochondria, accumulates on it, and

subsequently recruits PARKIN from the cytosol and instigates its E3 ubiquitin ligase activity by its kinase activity to trigger a cellular process for a selective degradation of mitochondria by autophagy (Kondapalli et al. 2012).

PINK1 functions as a kind of molecular sensor, monitoring the internal state of individual mitochondria and flagging damaged mitochondria for removal (Matsuda et al. 2010). With respect to PINK1 roles in mitophagy, the damage-sensing mechanisms arise from the localization-dependent degradation of PINK1 in healthy mitochondria within a cell, which regulates PINK1 cytoplasmic concentration (Thomas et al. 2014). Under normal steady-state conditions, PINK1 is imported into the outer mitochondrial membrane (OMM) and thereby inner mitochondrial membrane (IMM), respectively, through the translocase of the outer membrane (TOM) and translocase of the inner membrane (TIM) complexes, cleaved by the IMM protease called Presenilin-associated rhomboid-like protein (PARL) and another mitochondrial processing peptidase (MPP), and subsequently degraded by the ubiquitin–proteasome system. This mechanism causes an undetectable concentration of PINK1 molecules on healthy mitochondria (Greene et al. 2012; Jin et al. 2010; Meissner et al. 2011). See Fig. 2a.

It has appeared that electrical component of the inner mitochondrial membrane potential ($\Delta\Psi$) is crucial for the direction of PINK1 towards mitochondrial membrane and for its import into mitochondrial matrix compartment. The collapse of $\Delta\Psi$ blocks the TOM/TIM import pathway and in turn, prevents PARL/MPP rapid degradation mechanism causing PINK1 to accumulate uncleaved on the OMM, and binds to the outer mitochondrial membrane proteins such as TOM complex. When PINK1 becomes stable on the OMM, recruits PARKIN and activates its E3 ubiquitin ligase activity to enable OMM proteins polyubiquitination (Lazarou et al. 2012; Okatsu et al. 2013; Youle and Narendra 2011). Figure 2b shows that PINK1-mediated recruitment and activation of PARKIN occurs through Ser65 phosphorylation within the ubiquitin-like (Ubl) domain of PARKIN (Kazlauskaitė et al. 2014). However, several recent biochemical investigations found that this process can be accelerated when PARKIN Ser65 phosphorylation combined with ubiquitin Ser65 phosphorylation (Kane et al. 2014). A model is presented for this positive feedback showing that phospho-ubiquitin generated by PINK1 (not unmodified ubiquitin) likely functions as an allosteric effector, binds to PARKIN allosteric site, and regulates its E3 ubiquitin ligase activity in a positive manner (Koyano et al. 2014). Once PARKIN is activated, it modifies various proteins on the OMM (36 substrates have been identified to date) and in the cytosol with K48- and K63-linked ubiquitin chains and thereby facilitates recruitment of specific autophagic receptor to ultimately degrade damaged mitochondria (Chan et al. 2011; Sarraf et al. 2013).




Fig. 2 **a** Mitochondrial membrane potential ($\Delta\Psi$) directs PINK1 towards OMM. PINK1 is continuously imported into mitochondria through the TOM/TIM complexes and subsequently targeting signal is cleaved and degraded by PARL and MPP, respectively. The trun-

cated PINK1 is degraded by the ubiquitin proteasome system; **b** collapse of $\Delta\Psi$ blocks the TOM/TIM import pathway. PINK1 becomes stable on the OMM and recruits Parkin and activates its E3 ubiquitin ligase activity through the phosphorylation of Parkin on Ser65


It has been reported that PINK1/PARKIN pathway facilitates mitophagy by altering mitochondrial trafficking (Xinnan Wang et al. 2011). Miro1 is a mitochondrial outer membrane protein that forms a complex with Milton and Kinesin to promote mitochondrial trafficking on microtubules (Boldogh and Pon 2007; Frederick and Shaw 2007). It has been demonstrated that PINK1 phosphorylates Miro1 on Ser156 to induce PARKIN and proteasomal degradation of it, releasing Milton/Kinesin complex from mitochondrial surface and leading to arrest dysfunctional mitochondria motility in neurons (Liu et al. 2012; Xinnan; Wang et al. 2011). This is considered as an initial quarantining step prior to mitophagy. See Fig. 3c.

Also, PINK1/PARKIN pathway appears to selectively affect the dynamics of dysfunctional mitochondria within the cell through the regulation of fusion/fission machinery as a mitochondrial quality control measure (Chen and Dorn 2013; Poole et al. 2008; Yu et al. 2015). In mammals, mitochondrial fusion was identified to be regulated by three

membrane-bound GTPases, including mitofusins (Mfn) 1 and 2 for OMM fusion and optic atrophy 1 (OPA1) for IMM fusion (Chen et al. 2003; Song et al. 2007). PINK1 was reported to phosphorylate Mfn2 at Thr111 and Ser442 to induce PARKIN and subsequent proteasomal degradation of Mfn2 (Chen and Dorn 2013). It seems that PINK1/PARKIN pathway inhibits mitochondrial fusion through the degradation of Mfn1/2 and prevents damaged mitochondria fusing with healthy mitochondria. Such isolation of dysfunctional mitochondria from the healthy mitochondrial network is considered as an essential step prior to induction of mitophagy (Gegg et al. 2010; Poole et al. 2010). See Fig. 3b.

Although PINK1/PARKIN pathway affects mitochondrial dynamics and trafficking by proteasomal degradation of specific mitochondrial outer membrane proteins (OMM proteins with K48-linked ubiquitin chains), it appears to target the entire mitochondria for autophagic degradation by selective recruitment of adaptor proteins to other mitochondrial outer membrane substrates (OMM proteins with K63-linked

Fig. 3 Schematic representation of three pathways that PINK1/PARKIN controls hemostasis of mitochondria; **a** PINK1/PARKIN pathway targets the entire mitochondria for autophagic degradation by attaching ubiquitin chains to some outer mitochondrial membrane (OMM) proteins; **b** PINK1/PARKIN pathway induces proteasomal degradation of Mfn1/2 and isolates dysfunctional mitochondria from the healthy mitochondria; **c** PINK1/PARKIN pathway releases Milton/Kinesin complex from mitochondrial surface through the proteasomal degradation of Miro1, and leading to arrest dysfunctional mitochondria motility



ubiquitin chains) (Narendra et al. 2012). There is a leading hypothesis that the ubiquitin chains attached by PARKIN to some OMM proteins or mitophagy receptors including BNIP3L (BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like), FUNDC1 (FUN14 domain-containing protein 1), and BCL2L13 (BCL2-like 13) serve as a positive signal for several different proteins such as p62/SQSTM1 (Sequestosome 1), NBR1 (Neighbor of BRCA1), NDP52 (Nuclear dot protein 52 kD), and OPTN (Optineurin) and recruit them to OMM (Gao et al. 2015; Geisler et al. 2010; Heo et al. 2015; Liu et al. 2012a, b; Otsu et al. 2015). These proteins function as adaptor proteins and bind both to ubiquitin chains and LC3/GABARAP (Gamma-aminobutyric acid receptor-associated protein) family members, which in turn recruit different protein complexes to growing isolation membranes that expand alongside mitochondria. The mechanisms involved in phagosome expansion are probably mediated by phagosome membrane uptake through the interaction of LC3/GABARAP with the autophagosome membrane and autophagy protein complex, ATG12-ATG5-ATG16L (Kabeya et al. 2004; Yang and Klionsky 2010). On the other hand, recent studies have uncovered that three mitochondrial localized proteins including RabGAPs, TBC1D15 (TBC1 Domain Family Member 15), and TBC1D17 (TBC1 Domain Family Member 17) bind to the mitochondrial outer membrane protein Fission1 via interaction with LC3/GABARAP and leads to positive regulation of autophagosomal membrane engulfment of mitochondria. The autophagosome then fuses with a lysosome, leading to degradation of the dysfunctional mitochondria by the proteases and lipases that reside in lysosomes (Shen et al. 2014; Yamano et al. 2014). See Figs. 1c, 3b, and 4.

DJ-1

Mutations in the *DJ-1* gene are known to be associated with rare cases of autosomal recessive PD (1% of early-onset PD) (Bonifati et al. 2003). Clinically, patients affected with *DJ-1* mutations were found to have an early asymmetric development of dyskinesia, hyperreflexia, rigidity, and tremor, with later psychiatric symptoms including, psychotic disturbance, cognitive decline (uncommon), anxiety, and also a good response to L-DOPA (similar to clinical and phenotypic features of patients with *PARKIN* and *PINK1* mutations) (Abou-Sleiman et al. 2003; Annesi et al. 2005; Bonifati et al. 2003; Ibáñez et al. 2006). *DJ-1* encodes a protein involved in transcriptional regulation and antioxidative stress reaction within the neuronal cells (Ottolini et al. 2013). Under normal condition, subcellular localization investigations have revealed that DJ-1 is predominantly located in the cytoplasm and to a lesser extent in the nucleus and mitochondria within the neuronal cells (Junn et al. 2009; Nagakubo et al. 1997; Zhang et al. 2005). However, Junn et al. (2009) recently observed that DJ-1 translocation into the nuclear compartment is enhanced in response to oxidative stress (Junn et al. 2009). It has proven that the activation and subsequently nuclear localization of DJ-1 protects cells against reactive oxygen species (ROS), which is followed by self-oxidation at cysteine 106 (C106), a highly susceptible residue to oxidative stress (oxidative stress sensor residue), and formation of cysteine–sulfonic acid (SOH, SO₂H) upon exposure to oxidative stress (Canet-Avilés et al. 2004; Kim et al. 2012; Kinumi et al. 2004). In addition, several studies have reported that under excessive oxidative stress conditions, DJ-1 is oxidized as SO₃H at cysteine 46 (C46), cysteine 53




Fig. 4 Schematic representation of the phagosome membrane formation around the damaged mitochondria. Refer to the text for explanations

(C53), and cysteine 106 (C106) residues, which is an inactive form of DJ-1 observed in brains of patients with PD and Alzheimer's disease (Bandopadhyay et al. 2004; Choi et al. 2006; Kinumi et al. 2004; Zhou et al. 2006).

In response to oxidative stress, DJ-1 in its oxidized form, acts as a neuroprotective transcriptional coactivator and regulates the activity of several DNA-binding transcription factors (TFs) including nuclear factor erythroid-2-like 2 (NFE2L2), polypyrimidine tract-binding protein-associated splicing factor (PSF) and p53 (Clements et al. 2006; Fan et al. 2008a, b; Zhong et al. 2006). Several lines of evidence obtained from separate studies suggesting that the TFs whose activity is regulated by DJ-1 may trigger multiple cytoprotective pathways against oxidative stress and subsequent neuronal cell death (Martinat et al. 2004; Venderova and Park 2012).

Investigation of ROS metabolism in human umbilical vein endothelial cells (HUVECs) has shown that NFE2L2 serves as a master TF for cellular antioxidant functions and detoxification responses (Kinumi et al. 2004). Without oxidative stresses, NFE2L2 is localized in the cytoplasm and interacts with KEAP1, which is an inhibitor protein and promotes ubiquitin–proteasome degradation of NFE2L2. Upon oxidative stress, DJ-1 disrupts the NFE2L2-KEAP1 interaction to stabilize NFE2L2, leading to translocation of

NFE2L2 into the nucleus (Clements et al. 2006). This process is essential for the expression of several detoxifying and antioxidant enzyme genes through the binding of NFE2L2 to the antioxidant response elements (AREs) in their promoters, and thereby increasing neural protection against DNA damage and apoptosis (Im et al. 2012; Kensler et al. 2007; Vargas and Johnson 2009).

Tyrosine hydroxylase (TH) is a rate-limiting enzyme for dopamine synthesis and its deficiency contributes to the typical clinical symptoms of PD. Several protein-interaction studies have suggested that DJ-1 and PSF bind and transcriptionally regulate the human TH promoter (Ishikawa et al. 2009, 2010). Western blot analysis of SUMO species using immunoprecipitated PSF has demonstrated that PSF is sumoylated in human dopaminergic neuroblastoma SH-SY5Y cell lines. Sumoylation of PSF leads to the recruitment of histone deacetylase (HDAC) 1 to TH promoter and increase deacetylation of the TH promoter-bound histones, which subsequently results in the loss of TH expression and dopamine production. It has proven that DJ-1 positively regulates human TH gene expression by blocking the sumoylation of PSF and subsequently preventing HDAC1 recruitment to the TH promoter (Xu et al. 2005; Zhong et al. 2006). In addition, DJ-1 has been shown to stimulate vesicular monoamine transporter 2 (VMAT2) activities by

transcriptional upregulation of VMAT2 gene and by direct binding to VMAT2 protein. VMAT2 is an integral membrane protein that transports cytosolic dopamine, a highly reactive molecule, into synaptic vesicles to avoid the effect of autoxidized dopamine on neuronal cell degeneration. These findings support the theory that stimulating activity of DJ-1 toward VMAT2 contributes to the protective reaction against dopamine toxicity (Ishikawa et al. 2012).

The p53 functions as a tumor suppressor protein and plays major roles in suppression of cell growth in response to stress conditions by induction of either cell cycle arrest or apoptosis. Human topoisomerase I-binding protein (Topors) is defined as a rate-limiting factor in the regulation of p53 activity. Under stress conditions, Topors acts as a coactivator of p53 and induces cell cycle arrest or apoptosis through enhancing the transcription of p53 downstream genes including Bax and p21 (Hofseth et al. 2004; Lin et al. 2005). DJ-1 has been shown to inhibit the induction of apoptosis by p53 through inhibition of Topors activity. It has also been reported that DJ-1 directly binds to the DNA-binding region of p53 and represses p53 transcriptional activity on Bax and p21 promoters, leading to neural cell cycle progression (Fan et al. 2008a, b; Kato et al. 2013).

It is suggested that DJ-1 involves within the cytoprotective pathways against oxidative stress and mutations in it cause the progressive apoptotic death of neuron cells, which can eventually lead to early onset of PD symptoms.

LRRK2

Mutation in *Leucine-rich repeat kinase2 (LRRK2)* gene is known as one of the common genetic cause of PD (Healy et al. 2008); they are responsible for at least 4% of autosomal dominant forms of familial PD typically associated with late onset and are also found in 1% of sporadic PD worldwide (Di Fonzo et al. 2005; Gilks et al. 2005; Nichols et al. 2005). Patients affected with *LRRK2* mutations exhibit a broad spectrum of clinical and phenotypic features including bradykinesia, muscular rigidity, tremor, cognitive decline, moderate dementia, olfactory deficits, hallucinations, sleep disturbance, orthostatic hypotension, and appreciable response to L-DOPA (Alcalay et al. 2009; Wszolek et al. 1995). However, several studies have reported that Lewy bodies (the pathological hallmarks of PD) are absent in some PD patients affected with *LRRK2* mutations (Funayama et al. 2005). The *LRRK2* gene encodes a large multifunction with important kinase activities. Some PD-associated mutations to *LRRK2* result in increased kinase activity of the protein, which may suggest a toxic gain of function mechanism. Wang et al. (2012) found that *LRRK2* regulates mitochondrial dynamics by interacting with a number of key regulators of mitochondrial fission/fusion, on mitochondrial membranes (Xinglong Wang et al. 2012). Wild-type *LRRK2* gene

expression studies in human neuronal cell lines concluded that endogenous *LRRK2* directly interacts with dynamin-related protein 1 (DRP1), a mitochondrial fission protein, increasing DRP1 phosphorylation and mitochondrial fission (Saez-Atienzar et al. 2014; Xinglong; Wang et al. 2012). The *LRRK2*-DRP1 interaction was enhanced by overexpressing wild-type *LRRK2* and by *LRRK2* PD-associated mutations (Su and Qi 2013; Xinglong; Wang et al. 2012). Also, it has been recently shown that *LRRK2* modulates mitochondrial fusion regulators Mfn1/2 and OPA1 activities by interacting with them at the mitochondrial membrane. Additionally, decreased levels of reactive OPA1 have been observed in sporadic PD patients carrying some *LRRK2* pathogenic mutations (Stafa et al. 2013). Increased kinase activity of *LRRK2* results in aberrant increased mitochondrial fragmentation which was associated with mitochondrial dysfunction, increased ROS production from mitochondrial complexes, and subsequently enhanced susceptibility to oxidative stress. These observations suggest that altered mitochondrial fission/fusion which is caused by mutations in *LRRK2* gene is an important factor in the pathogenesis of PD.

HTRA2/OMI

High-temperature requirement A2 (HTRA2/OMI) is another attractive candidate gene for PD that encodes a serine protease localizing to the mitochondrial intermembrane space (IMS). A heterozygous G399S missense mutation in the coding sequence of the gene was first identified in four German patients with PD (Strauss et al. 2005). However, evidence for the pathogenesis of *HTRA2/OMI* in PD has been further supported by whole exome sequence analyses in patients with PD from the Taiwan, Pakistan, Mexico, and in affected infants, born of consanguineous parents of Druze and Ashkenazi origins (Lin et al. 2011; Mandel et al. 2016; Oláhová et al. 2017). Also, some phenotypic similarities with parkinsonian features, including motor abnormalities and the progressive neurodegeneration in some brain regions, especially in the striatum were observed in *HTRA2/OMI* loss-of-function mice, indicating that *HTRA2/OMI* can serve a neuroprotective function (Jones et al. 2003; Martins et al. 2004). Loss of *HTRA2/OMI* protease activity in *OMI*-knockout mouse embryonic fibroblast cells showed increased mitochondrial DNA mutation, decreased mitochondrial membrane potential, altered mitochondrial morphology, and reduced mitochondrial density (Kang et al. 2013; Rathke-Hartlieb et al. 2002). It has been proposed that *HTRA2/OMI* is involved in the quality control of the proteins targeted for mitochondrial IMS by proteolysis of misfolded and damaged proteins, which is induced upon proteotoxic stress (Walle et al. 2008). In addition, it has been demonstrated that in mammalian cells *HTRA2/OMI* is released from mitochondria to the cytosol in response to apoptotic

stimuli and induces apoptosis through interaction and proteolytic elimination of inhibitor of apoptosis proteins including c-IAP1 and XIAP (Suzuki et al. 2001; Yang et al. 2003). However, under nonapoptotic conditions, the HTRA2/OMI is restricted to the mitochondrial IMS and is also implicated in mitochondrial protein quality control (Cilenti et al. 2014; Kieper et al. 2010). These findings provided a link between mutations in *HTRA2/OMI* gene and mitochondrial dysfunction which is associated with neurodegeneration seen in some patients with PD (Bogaerts et al. 2008).

CHCHD2

More recently, evidence for the role of mitochondrial dysfunction in the pathogenesis of Parkinson's disease was further confirmed, based on the identification of heterozygous mutation in the *coiled-coil-helix-coiled-coil-helix domain 2* (*CHCHD2*) gene using whole genome analysis in a Japanese family with autosomal dominant Parkinson disease. Clinical features of the patients usually include PD typical symptoms such as tremor, bradykinesia, rigidity, postural instability, and a good response to L-DOPA treatment (Funayama et al. 2015). This gene encodes a protein that is active in two cellular compartments including mitochondria and nucleus and is involved in the regulating mitochondrial metabolism under conditions of oxygen stress (Aras et al. 2015). In normal conditions, CHCHD2 is predominantly present within the mitochondrial intermembrane space (MIS) and binds to the subunit 4 of cytochrome C oxidase (COX4), which is necessary for optimal COX activity. COX is the last enzyme present in the electron transfer chain and plays a key role in the process of respiration within the mitochondrial membrane. In fact, its interaction with CHCHD2 plays a key role in maintaining energy balance inside the neurons under hypoxic conditions, by increasing COX4 efficiency and producing appropriate energy in the form of ATP via oxidative phosphorylation (Aras et al. 2013). Consistent with these observations, knockdown of CHCHD2 expression in human fibroblasts led to mitochondrial dysfunctions through reduced COX4 activity, oxygen consumption, and mitochondrial membrane potential, and increased ROS and mitochondrial fragmentation. Also, CHCHD2 functions as a master transcription factor to cope with oxidative stress. DNA-binding assays indicated that CHCHD2 binds to the proximal promoter of *COX4* gene as an oxygen responsive element (ORE) to increase its transcription. In addition, these studies revealed that CHCHD2 participates in a positive feedback loop and increases its expression through binding to ORE in its own promoter. It has been proven that although, a small portion of CHCHD2 is present in the nucleus under normal conditions, during the course of continuous oxidative stress the translocation of CHCHD2 into the nucleus is further stimulated in order to promote

itself and COX gene transcription as anti-hypoxic responses (Aras et al. 2015, 2013). Furthermore, it has been reported that CHCHD2 binds to the Bcl-xL and regulates its activity in order to inhibit induction of apoptosis by the accumulation of Bax on the mitochondrial membrane under oxidative stress conditions (Liu et al. 2015). It is proposed that mutations in *CHCHD2* gene impair neuroprotection responses against hypoxic stress conditions through disruption of mitochondrial metabolism, thereby increasing the ROS level and also induction of apoptosis by Bax.

VPS13C

Recently, whole genome studies in the field of Parkinsonism revealed that mutations in *vacuolar protein sorting 13C* (*VPS13C*) are associated with the development of autosomal recessive early-onset forms of PD. Clinically, patients affected with *VPS13C* mutations show the rapid and severe progression of bradykinesia, tremor, cognitive decline, and autonomic dysfunctions as well as a good response to L-DOPA treatment at the early stage (Lesage et al. 2016; Nalls et al. 2014). It has been proven that *VPS13C* encodes a member of a family of vacuolar protein sorting 13 (VPS13) (Velayos-Baeza et al. 2004). Currently, the molecular pathway(s) underlying how mutations in *VPS13C* cause PD remain unknown. However, in vitro experiments on human cell models showed that VPS13C is located on the outer mitochondrial membrane. Also, knockdown of *VPS13C* in the animal cell models is markedly associated with lower mitochondrial membrane potential, increased ROS, mitochondrial fragmentation, abnormal mitochondrial morphology, and upregulation of the expression of *PARKIN* and *PINK1* genes in response to toxin-induced mitochondrial dysfunction. It is believed that VPS13C cooperates with *PARKIN/PINK1* pathway and contributes to the selective delivery of damaged mitochondria cargo to the lysosome (Lesage et al. 2016; Schreglmann and Houlden 2016). In fact, it is proposed that mutations in *VPS13C* gene may lead to the increased amount of ROS and dysfunctional mitochondria and ultimately trigger neuronal cell death.

UCHL1

Ubiquitin C-terminal hydrolase L1 (*UCHL1*) encodes a highly neuron-specific member of a gene family whose products function in the ubiquitin recycling pathway by hydrolyzing polymeric ubiquitin chains into monomers. The presence of UCHL1 in Lewy bodies and its function in the proteasome pathway suggested that it could be a compelling PD candidate gene. A heterozygous I93M mutation in the *UCHL1* gene was found in affected members of a German family with autosomal dominant Parkinson disease. Clinical manifestations such as tremor,

muscular rigidity, bradykinesia, and postural instability, as well as good response to L-DOPA treatment, were typical for PD (Healy et al. 2004; Leroy et al. 1998). In vitro analysis showed that the mutant allele of *UCHL1* had ~50% reduced hydrolytic activity compared with the wild-type enzyme (Kensler et al. 2007; Nishikawa et al. 2003). Additionally, reduced levels of monoubiquitin in neurons were detected among the mice with neuroaxonal dystrophies, in which the function of *UCHL1* was lost (Saigoh et al. 1999). However, in neuronal cell culture and mice, the expression of *UCHL1* demonstrated an increase in the level of ubiquitin within the neurons (Osaka et al. 2003). These findings led to conclude that *UCHL1* may play a role in ubiquitin stability within neurons, which is critical for ubiquitin–proteasome system and neuronal survival (Meray and Lansbury 2007).

GBA

Several studies reported Parkinsonism in patients with Gaucher's disease (GD), a lysosomal storage disorder caused by mutations in *Glucocerebrosidase (GBA)* gene (Grabowski 2008). Moreover, in some families affected with GD, several relatives of the probands developed Parkinsonism, many of whom were obligate heterozygous carriers of the *GBA* mutant alleles. The patients had an atypical onset of PD, including cognitive defects and hallucination. However, the disorder was progressive, and later they developed asymmetric manifestation of tremor, muscular rigidity, bradykinesia, and postural instability. It has been suggested that some *GBA* mutations may be a risk factor for the development of Parkinsonism in these families (Goker-Alpan et al. 2004; Sidransky 2004). The link between *GBA* and PD was also supported by neuropathology studies, showing dopaminergic neuronal dysfunction with widespread pathologies of α -synuclein and Lewy body in patients with homozygous and heterozygous *GBA* mutation (Kono et al. 2007). In addition, detailed biochemical studies showed significant decrease in glucocerebrosidase enzyme (GCCase) activity and increase in α -synuclein accumulation in PD brains, with *GBA* mutations. GCCase catalyzes the breakdown of sphingolipid glucosylceramide to ceramide and glucose within lysosomes and reduced enzyme activity and mutant protein may lead to impaired lysosomal protein degradation and increased exosomal release of α -synuclein and formation of its related toxic aggregates (Lin and Farrer 2014; Mazzulli et al. 2011; Schapira and Jenner 2011; Xu et al. 2011). See Fig. 1b. However, in line with these findings, most recent studies reported that the homozygous or heterozygous *GBA* mutations lead to a 20- to 30-fold increase in the risk of PD and 5–10% of PD patients have mutations in *GBA* gene (Velayati et al. 2010).

ATP13A2

Originally, *ATPase type 13A2 (ATP13A2)* has been reported associated with Kufor–Rakeb syndrome (KRS), which is a severe early-onset PD, inherited in an autosomal recessive manner. Clinically, patients affected with KRS tend to show progressive brain atrophy, tremor, rigidity, bradykinesia, dystonia, dementia, cognitive impairment, depression, supranuclear gaze palsy, and a better response to L-DOPA (Al-Din et al. 1994; Crosiers et al. 2011; Williams et al. 2005). *ATP13A2* gene belongs to the 5P-type subfamily of ATPase and encodes a lysosomal transmembrane protein that is mainly expressed in the brain. To date, the biochemical findings of *ATP13A2* represent a class of proteins with unassigned function and substrate specificity (Dehay et al. 2012; Murphy et al. 2013; Ramirez et al. 2006). However, several different studies on the cultured KRS-patient dermal fibroblasts and other types of *ATP13A2*-deficient cell lines such as human neuroblastoma SHSY5Y cells determined that loss of functional *ATP13A2* leads to instability of the lysosomal membrane and subsequently impaired lysosomal proteolysis function, which is essential to the lysosomal-mediated proper protein and mitochondrial quantity and quality control pathways within neurons (Dehay et al. 2012; Gusdon et al. 2012; Tofaris 2012); see Fig. 1d. These defects are tightly associated with pathogenic accumulation of α -synuclein and mitochondrial dysfunction, resulting in decreased ATP production and increased intracellular levels of ROS that contribute to the neuronal cell death (Gitler et al. 2009; Grünwald et al. 2012; Kong et al. 2014). In addition, several other studies have identified abnormal accumulation of manganese (Mn^{2+}) and zinc (Zn^{2+}) in the brain and cerebrospinal fluid of PD patients affected with *ATP13A2* mutations (Fukushima et al. 2011; Hozumi et al. 2011; Jiménez-Jiménez et al. 1992). Moreover, Tan et al. (2011) found that overexpression of *ATP13A2* in cultured neuronal cells exposed to Mn^{2+} reduced intracellular Mn^{2+} concentrations and protected cells from subsequent apoptosis (Tan et al. 2011). It is believed that *ATP13A2* protects cells from metal toxicity by providing homeostasis of Mn^{2+} and Zn^{2+} (the significant environmental risk factors for PD) within neurons (Guilarte 2010; Pals et al. 2003; Rentschler et al. 2012).

It is speculated that mutations in *ATP13A2* may disrupt normal intracellular homeostasis of divalent cations and lead to lysosomal and mitochondrial defects within neurons and ultimately significant neurodegeneration that is the distinguishing pathological feature of PD.

PLA2G6

Phospholipase A2 group 6 (PLA2G6) has been characterized as the causative gene for different neurodegenerative

diseases, including infantile neuroaxonal dystrophy (INAD), neurodegeneration with brain iron accumulation (NBIA), and Karak syndrome. However, recent genetic analysis of affected families from India, Iran, and Pakistan has been reported that mutations in the *PLA2G6* gene are responsible for early-onset dystonia-Parkinsonism with autosomal recessive inheritance (Morgan et al. 2006; Paisan-Ruiz et al. 2009; Paisán-Ruiz et al. 2010; Sina et al. 2009). The main clinical features of the patients affected with *PLA2G6* mutations are tremor, muscular rigidity, bradykinesia, dystonia, brain atrophy, dementia, visual disturbance, good response to L-DOPA therapy at first, and later L-DOPA-induced dyskinesia (Paisan-Ruiz et al. 2009; Sina et al. 2009; Yoshino et al. 2010). It has been proven that *PLA2G6* gene encodes calcium-independent group 6 phospholipase A2 enzyme, which hydrolyzes the *sn*-2 ester bond of the membrane glycerophospholipids to yield free fatty acids and lysophospholipids (Balsinde and Balboa 2005). This function has profound effects on the repair of oxidative damage to the cellular and subcellular membrane phospholipids, membrane fluidity, and maintenance of membrane permeability or iron homeostasis (Balsinde and Balboa 2005; Shinzawa et al. 2008). In addition, Beck et al. (2015, 2016) demonstrated that knocking out the *PLA2G6* gene in mice leads to defects in remodeling of mitochondrial inner membrane and presynaptic membrane and subsequently causes mitochondrial dysfunction, age-dependent degeneration of dopamine nerve terminals, synaptic dysfunction, and significant iron accumulation in the brains of *PLA2G6* knockout mice (Beck et al. 2016, 2015). These findings suggest that impairment of the dopaminergic nervous system and brain iron accumulation caused by mutations in the *PLA2G6* gene can be considered as a pathogenic mechanism in sporadic and familial PD (Kauther et al. 2011).

VPS35


In 2011, pathogenic mutations in the *vacuolar protein sorting 35* (*VPS35*) gene have been reported as novel causes of autosomal dominant PD, by application of whole exome sequencing to a large Swiss kindred representing late-onset tremor-predominant Parkinsonism (Vilariño-Güell et al. 2011). The main phenotypes associated with *VPS35* mutations in this kindred were tremor, dyskinesia, rigidity, dystonia, and good response to L-DOPA with rare cognitive or psychiatric symptoms (Kumar et al. 2012). Recent studies indicate that *VPS35* gene encodes a core component of the retromer cargo-recognition complex and plays a critical role in cargo retrieving pathway from the endosome to the trans-Golgi network (TGN) (Fuse et al. 2015; Tsika et al. 2014; Zavodszky et al. 2014). It has been proven that Cation-independent mannose 6-phosphate receptor (CI-MPR) is one of the best characterized cargo proteins of the retromer

complex, which is involved in the trafficking of lysosomal proteases, such as the cathepsin D (CTSD), to lysosomes (Bugarcic et al. 2011; Choy et al. 2012; Seaman 2007). Under normal conditions, CTSD is specifically modified by attaching mannose 6 phosphates (M6P) residues to its signal peptide (M6P-CTSD) inside the TGN (Miura et al. 2014). Subsequently, M6P-CTSD is recognized by the CI-MPR and is trafficked from the TGN to the endosome. Inside the endosome, CTSD is activated by proteolytic cleavage of the signal peptide and then is released for further traffic to the lysosome. Ultimately, retromer retrieves free CI-MPRs from the endosome to the TGN, in which they can be involved in further cycles of CTSD trafficking to the lysosome (Laurent-Matha et al. 2006; Miura et al. 2014). It seems that dominant negative mutations in *VSP35* cause retromer complex dysfunction and lead to decreased delivery of CTSD to the lysosome and subsequently impaired lysosomal proteolysis function which is essential to the lysosomal-mediated proper protein quality control pathways (Follett et al. 2014; Fuse et al. 2015; Hernandez et al. 2016). In addition, Miura et al. (2014) demonstrated that knocking down the *VPS35* gene in *Drosophila* leads to the toxic accumulation of the α -synuclein within the neurons which can further support the role of *VPS35* in the pathogenesis of PD (Miura et al. 2014). See Fig. 5.

FBXO7

In 2008, *F-box protein 7* (*FBXO7*) was identified as a novel PD causative gene by a genome-wide linkage analysis in a large Iranian family, affected with autosomal dominant early-onset PD (Shojaee et al. 2008). Also, homozygote and compound heterozygote loss-of-function mutations in *FBXO7* have been reported in Italian and Dutch families. Affected members usually showed tremor, rigidity, bradykinesia, postural instability, hyperreflexia, saccadic eye movement with normal cognition, and appreciable response to L-DOPA (Di Fonzo et al. 2009a, b). To date, the precise mechanism by which *FBXO7* contributes to neurodegeneration process remains poorly defined. However, it has been proven that *FBXO7* functions as a molecular scaffold in the formation of protein complexes. *FBXO7* has been reported to mediate the formation of SCF (Skp1, Cullin1, F-box protein) ubiquitin ligase complexes, and plays roles in the ubiquitin–proteasome degradation pathway (Nelson et al. 2013). In addition, recent invitro analyses have identified that *FBXO7* physically interacts with *PARKIN*. In this regard, biochemical findings in *Drosophila* showed that overexpression of wild-type *FBXO7* suppresses mitochondrial disruption and also neurodegeneration process in *PARKIN* mutants, confirming that they share a common role in mitochondrial biology (Burchell et al. 2013; Zhou et al. 2016). As a result, it is assumed that *FBXO7* functions in a common pathway

Fig. 5 a VPS35 is a core component of the retromer cargo-recognition complex and plays a critical role in cargo retrieving pathway from the endosome to the trans-Golgi network (TGN); **b** mutations in VSP35 cause retromer complex dysfunction and lead to decreased delivery of CTSD to the lysosome and subsequently impaired lysosomal proteolysis function; Refer to the text for more explanations



with PARKIN and PINK1 to induce selective autophagic clearance (mitophagy) in response to damaged mitochondria and pathogenic mutations in *FBXO7* may interfere with this pathway (Conedera et al. 2016; Randle and Laman 2017; Vingill et al. 2016).

EIF4G1

Originally, mutations in *Eukaryotic translation initiation factor 4 gamma, 1 (EIF4G1)* gene were identified in a large French family with autosomal dominant PD and confirmed in several families from the United States of America (USA), Canada, Ireland, Italy, and Tunisia. Clinically, affected individuals with *EIF4G1* mutations show late onset of asymmetric resting tremor, bradykinesia, muscle rigidity, with preserved cognition and good response to L-DOPA treatment (Chartier-Harlin et al. 2011). *EIF4G* gene family encodes a large scaffold protein that functions as a key initiation factor in mRNA translation and protein synthesis within eukaryotic cells by recruiting the multisubunit translation initiation factor complex at the 5' cap of mRNAs (Ali et al. 2001). *EIF4G1* is a member of *EIF4G* gene family which selectively regulates the cap-dependent translation initiation of a subset of mRNAs encoding proteins function in mitochondrial activity, cellular bioenergetics, cellular growth, and proliferation in response to different cellular stresses (Ramírez-Valle et al. 2008; Silvera et al. 2009). Also, it has been reported that the high levels of EIF4GI are associated with malignancy in a significant number of human breast cancers suggesting that overexpression of EIF4GI may specifically increase cell proliferation and prevent autophagy in some human cancers (Schneider and Sonenberg 2007). Moreover, the loss of mitochondrial membrane potential and biogenesis has been observed in *EIF4G1*-silenced cells subjected to hydroperoxide treatment. It has been proposed that mutations in *EIF4G1* impair the mRNA translation initiation in PD. In fact, such mutations alter the translation of existing mRNAs essential to neuronal cell survival and their abilities to rapidly and dynamically respond to stress (Chartier-Harlin et al. 2011).

GIGYF2

A genome-wide linkage analysis by use of 400 dinucleotide markers in a sample of sib pairs with late-onset autosomal dominant Parkinsonism found linkage to the 2q36–q37 chromosomal region (Pankratz et al. 2002). The marker with the highest linkage score (D2S206, LOD 5.14) was within the *Grb10-Interacting GYF Protein-2 (GIGYF2)* gene region (Tan and Schapira 2010). Later sequence analysis of the *GIGYF2* gene region in 12 unrelated familial PD patients from Italy and France revealed seven different heterozygous mutations in the *GIGYF2* gene, while these mutations were

absent in controls (Lautier et al. 2008). However, there is some controversy surrounding the role of *GIGYF2* gene in the pathogenesis of PD, since several recent studies did not provide strong evidence for the association between *GIGYF2* gene mutations and PD (Bras et al. 2008; Di Fonzo et al. 2009b; Guo et al. 2009).

Studies in cultured cells, as well as yeast two-hybrid analysis, revealed that *GIGYF2* may be recruited to activated-IGF-I/insulin receptors through binding to the N-terminus of Grb10 (Giovannone et al. 2003). Grb10 is recruited to tyrosine phosphorylated IGF-I/insulin receptors, in response to IGF-I/insulin stimulation (Dey et al. 1996; Hansen et al. 1996). It has been proven that Grb10 serves as an adaptor protein between NEDD4 and IGF-1 receptor and triggers ligand-induced ubiquitination and subsequent degradation of the IGF-I/insulin receptor (Langlais et al. 2004; Vecchione et al. 2003). Also, Overexpressing Grb10 gene in mice leads to postnatal growth retardation which further supports a role for the Grb10 protein in negatively regulating cell growth via the modulation of IGF-I/insulin receptor signaling (Dufresne and Smith 2005; Shiura et al. 2005). In contrast, expression of *GIGYF2* in cultured cells showed a significant increase in IGF-1-stimulated receptor tyrosine phosphorylation (Higashi et al. 2010). In fact, it is postulated that *GIGYF2* binding to Grb10 results in a significant increase in IGF-I/insulin receptor signaling pathway. In addition, a report showed that heterozygous *GIGYF2*+/- mice develop adult-onset neurodegeneration, indicating that *GIGYF2* gene dysfunction may have an important role in neurodegeneration process in the central nerve system (CNS) (Giovannone et al. 2003, 2009).

ATXN2

During the last decade, researches in the field of Parkinsonism have described an association between CAG repeat expansions within the coding region of *Ataxin-2 (ATXN2)* gene and dominantly inherited familial forms of PD (Gwinn-Hardy et al. 2000; Payami et al. 2003). Molecular genetic analyses in affected families have reported that normal *ATXN2* alleles contain 14–31 CAG repeats, whereas pathologic alleles may carry expanded CAG repeats ranging in size from 35 to more than 200 (Lu et al. 2004). Clinical examinations suggest that cerebellar ataxia is usually the predominant symptom among patients. However, they often show some parkinsonian symptoms such as tremor, rigidity, bradykinesia, saccadic eye movement disorder, and good response to L-DOPA (Lu et al. 2004; Ragothaman et al. 2004). Although the biochemical function of *ATXN2* is currently unknown, molecular studies in *Drosophila* suggest that *ATXN2* may play roles in transport, stability, and translation regulation of a subset of mRNAs within neurons (Al-Ramahi et al. 2007; Halbach et al. 2015; Satterfield and Pallanck 2006). It seems that CAG repeat expansions within

the coding sequences of *ATXN2*, resulting in the expansion of a polyglutamine (poly Q) tract in the *ATXN2* may cause translational dysregulation of particular mRNAs and subsequently trigger the degeneration of dopaminergic neurons within the brain (Nkiliza et al. 2016; Satterfield and Pallanck 2006).

DNAJC6

Autosomal recessive inheritance of mutations in the *DNAJC6* gene linked to juvenile-onset (< age 20) atypical Parkinsonism (PARK 19) has been reported. Disease progression in affected individuals was rapid, leading to a wheelchair-bound state within 10 years of onset. Response to L-DOPA was poor or absent and additional atypical manifestations such as mental retardation, seizures, dystonia, and pyramidal signs were observed (Edvardson et al. 2012; Koroglu et al. 2013). The *DNAJC6* gene codes for a brain-specific auxilin protein (Olgiati et al. 2016) which plays a role in the presynaptic endocytosis of clathrin-coated vesicles. The impairment of this pathway impacts on the formation of new vesicles at the presynaptic terminal (Kononenko and Haucke 2015). Variable phenotypes have been observed in PD patients expressing homozygous *DNAJC6* mutations with the onset of parkinsonian features occurring between the 3rd and 5th decade of life, disease progression being slower and with better responses to dopaminergic therapies. This separates patients markedly from PARK19 to be categorized as early-onset PD (< age 45) and suggests that some milder pathogenic mutations in the *DNAJC6* gene may allow for reduced auxilin expression (Olgiati et al. 2016).

SYNJ1

Mutations in the *SYNJ1* gene have been reported to cause juvenile-onset atypical Parkinsonism (PARK20) through autosomal recessive inheritance. Typical features occurring at a young age include bradykinesia, tremor, dystonia, and apraxia of eyelid opening (ALO) as well as cognitive decline and generalized seizures in some patients (Quadri et al. 2013; Krebs et al. 2013; Olgiati et al. 2014). The *SYNJ1* gene encodes synaptojanin-1, a presynaptic phosphoinositide phosphatase protein which has a role in the regulation of synaptic vesicle endocytosis, important in the recycling of proteins. Animal study has shown that mutations in the Sac phosphatase domain of *SYNJ1* led to Parkinson's-like neurological features and an increase in the levels of PD-associated proteins; auxilin, which has a similar role to synaptojanin-1 in endocytosis and PARKIN. The impairment of the endocytic recycling pathway led to an accumulation of proteins at synaptic terminals and it was observed to selectively result in dystrophic dopaminergic axon terminals in the dorsal striatum. Phenotypic

presentation in the animals studied provided strong evidence for a link between *SYNJ1* mutations and juvenile-onset PD, while elevated levels of auxilin and PARKIN suggesting an interaction with other PD-associated genes as a potential pathological mechanism (Cao et al. 2017).

DNAJC13

The *DNAJC13* gene encodes an endosomal protein involved in clathrin coating of vesicles and as such is involved in intracellular transport. Mutations have been reported through a dominant inheritance leading to PD in patients, characterized by α -synuclein positive Lewy bodies, with age of onset being between 40 and 83 years. Disease progression is slow with duration noted at between 8 and 17 years and L-DOPA only effective in earlier stages (Vilarino-Guell et al. 2014; Appel-Cresswell et al. 2014; Gustavsson et al. 2015; Ross et al. 2016). It has been hypothesized that the accumulation of α -synuclein is a direct result of impaired intracellular transport due to toxic gain-of-function mutations in the *DNAJC13* gene. This has been demonstrated in vivo using *Drosophila* models which linked mutant *DNAJC13* to increased levels of insoluble α -synuclein in the fly head, degeneration of dopaminergic neurons, and age-dependent locomotor deterioration (Yoshida et al. 2018).

PARK3, PARK 10, PARK 12

Several different genome-wide linkage analyses (GWLA) have been performed on the large groups of PD-affected families by genotyping of most popular genetic polymorphic markers including microsatellites and single-nucleotide polymorphisms (SNPs) (Funayama et al. 2015; Moghadam et al. 2017; Ott et al. 2015). Because PD is considered as a complex disease and causative loci may have different types of inheritance, the model of its inheritance is unknown (Keller et al. 2012). Therefore, linkage analysis based on model-free method would be more effective to map the loci responsible for the disease (Lander and Kruglyak 1995). In this approach, the PD-affected sibs inherited significantly more common alleles (identical by descent; IBD) at polymorphic loci linked to the disease than expected by chance (the expected probabilities of sharing 2, 1, and 0 IBD alleles for affected sib pairs at the disease locus will not be 0.25, 0.5, and 0.25, respectively) (Kruglyak et al. 1996; Nowak et al. 2012). As illustrated in Table 1, using model-free GWLA, three responsible loci for the PD have been mapped (*PARK3* on 2p13, *PARK10* on 1p32, and *PARK12* on Xq21-q25), but the causative genes have not yet been identified (DeStefano et al. 2002; Hicks et al. 2002; Pankratz et al. 2003).

Sporadic PD

In the last decade, investigation of patients affected with PD has revealed that a large number of patients suffer from sporadic forms of PD, showing nonMendelian inheritance pattern of the disease and lack of a clear family history with no clear distinction in clinical symptoms or pathological signs from familial forms (Kalinderi et al. 2016; Verstraeten et al. 2015). Early candidate gene studies have revealed that only a small percentage of the sporadic PD cases carry mutations in a number of previously known Mendelian PD genes including *SNCA*, *PARKIN*, *LRRK2*, and *GBA1* (Table 1) (Maraganore et al. 2006; Satake et al. 2009; Zabetian et al. 2009). However, the etiology for a high proportion of sporadic PD cases remains largely unknown. It is assumed that the sporadic forms of PD are caused by the combined effects of common variations (polymorphisms with frequencies > 1%) in different genetic loci with minor to moderate effects on PD risk (average odds ratios (ORs) ~1.2) (Simon-Sanchez et al. 2009; Simón-Sánchez et al. 2011). In order to uncover the genetic architecture that impacts disease susceptibility in sporadic cases, more than 800 genome-wide association studies (GWAS) have been performed in the field of Parkinsonism during the last two decades, but most studies yielded inconsistent results. To alleviate this problem, GWAS meta-analysis has recently successfully been developed as a systematic approach to interpreting the genetic association findings of complex disease including neurodegenerative diseases (Consortium 2011; Evangelou et al. 2007). In addition, GWAS meta-analysis on 7,782,514 genetic variants in up to 13,708 PD cases and 95,282 controls from populations of European descent have been provided by a dedicated and freely available online database,

PDGene (<http://www.pdgene.org>) (Lill et al. 2012). As illustrated in Table 2, twelve loci showed genome-wide significant association (ORs ≥ 1.1 ; p values $< 5 \times 10^{-8}$) with PD risk from case–control genotype data in 4 or more independent samples: *SNCA*, *TMEM175*, *STK39*, *TMEM229B*, *LRRK2*, *BCKDK*, *MIR4697*, *INPP5F*, *RIT2*, *GCHI*, *SIPA1L2*, *TMPRSS9* (Lill et al. 2012). However, despite this progress, the genetic etiology of PD, occurring in 40% of all cases remains unexplained by today (Consortium 2011).

Discussion

It is increasingly evident that Parkinson's disease (PD) is a complex and progressive neurodegenerative disorder clinically characterized by a broad spectrum of motor and non-motor impairments. Over the past decades, both familial and sporadic forms of PD have been identified, with overlapping phenotypes. Family-based studies have successfully identified 23 loci or genes associated with PD. Subsequent functional characterization of the encoded proteins has revealed that lysosomal dysfunction, impaired mitophagy, deficiency of synaptic transmission, and vesicular recycling pathways can be considered as the key molecular mechanisms in spreading pathology of the disease that may be shared between familial and sporadic forms of PD. Accumulating evidence indicates that gene mutations lead to various abnormalities in one or several of these subcellular pathways and associate with neuronal loss in the substantia nigra pars compacta (SNc). Now, based on the pathological studies, degeneration of dopaminergic neurons in the SNc and subsequent reduction in the striatal concentration of dopamine are accepted as being responsible for spread of pathological features in both sporadic and familial PD (motor features of

Table 2 GWAS meta-analyses results of the PDGene database in the populations of European descent

| Gene | Polymorphism | Location | Alleles | Case–control samples | Meta OR | Meta P-value |
|-----------------------------|--------------|-----------------|------------|----------------------|---------|--------------|
| <i>SNCA</i> [– 19139 bp] | rs356182 | chr4:90626111 | G versus A | 21 | 1.34 | 1.85e-82 |
| <i>TMEM175</i> | rs34311866 | chr4:951947 | C versus T | 21 | 1.26 | 6.00e-41 |
| <i>STK39</i> [+ 24494 bp] | rs1955337 | chr2:169129145 | T versus G | 21 | 1.21 | 1.67e-20 |
| <i>TMEM229B</i> | rs1555399 | chr14:67984370 | T versus A | 15 | 1.15 | 5.70e-16 |
| <i>LRRK2</i> | rs76904798 | chr12:40614434 | T versus C | 21 | 1.16 | 4.86e-14 |
| <i>BCKDK</i> | rs14235 | chr16:31121793 | A versus G | 21 | 1.10 | 3.63e-12 |
| <i>MIR4697</i> [– 3032 bp] | rs329648 | chr11:133765367 | T versus C | 21 | 1.11 | 8.05e-12 |
| <i>INPP5F</i> | rs117896735 | chr10:121536327 | A versus G | 13 | 1.77 | 1.21e-11 |
| <i>RIT2</i> | rs12456492 | chr18:40673380 | G versus A | 21 | 1.10 | 2.15e-11 |
| <i>GCHI</i> | rs7155501 | chr14:55347827 | A versus G | 15 | 1.12 | 1.25e-10 |
| <i>SIPA1L2</i> | rs10797576 | chr1:232664611 | T versus C | 21 | 1.13 | 1.76e-10 |
| <i>TMPRSS9</i> [– 26450 bp] | rs62120679 | chr19:2363319 | T versus C | 13 | 1.14 | 2.52e-09 |

PD are mainly related to the dopamine deficit in the striatum, as dopamine plays a significant role in the control of motor function within brain (Dickson et al. 2009). However, currently, there is no decisive description for why these disruptions affect dopaminergic neurons earlier and more profoundly than other neurons. One major common supposition for the selective vulnerability of SNc cells is the dopamine toxicity hypothesis. Dopamine metabolism is considered as a hot spot for the selective susceptibility of SNc cells to degeneration in PD (Segura-Aguilar et al. 2014). Dopamine metabolism produces highly reactive species and is vulnerable to different subcellular dysfunctions (Sulzer 2007). It is proposed that mitochondrial functional defects cause alterations in the mitochondrial respiratory chain as the main source of superoxide and hydrogen peroxide inside the neurons, and lead to the propagation of free radicals contributing to the oxidation of dopamine (Brieger et al. 2012). Also, deficiencies in the efficient elimination of damaged proteins or organelles (autophagy) due to impaired lysosome degradation pathway can lead to toxic protein aggregation and defective mitochondria accumulation inside the neuron which is associated with increased ROS formation as well as protein oxidation and enhanced vulnerability to oxidation of dopamine (Cook et al. 2012; Schapira et al. 2014). Moreover, it has been proven that reduced synaptic plasticity or impaired packaging of dopamine into the synaptic vesicles leads to an increased amount of cytosolic dopamine, which is readily susceptible to oxidation, and cause dopamine-mediated toxicity within the neurons (pH is lower inside the vesicles and dopamine cannot auto-oxidize) (Caudle et al. 2007; Zucca et al. 2014). Indeed, based on these observations, an emerging concept is that different gene mutations and subsequent mitochondrial dysfunctions, impaired lysosome degradation pathways, and reduced sequestration of dopamine into synaptic vesicles increase oxidative stress and interact with dopamine metabolism, which cause an exponential growth in the formation of highly reactive species of oxidized dopamine and precipitate lipid, protein, DNA, and other intracellular and membrane compounds oxidation as a critical step in the selective dopaminergic neuron death in the SNc over time (Jenner 2003; Segura-Aguilar et al. 2014).

In the past 30 years, this view that striatal dopamine loss secondary to degeneration of dopaminergic neurons might contribute to the pathogenesis of PD has guided the existing strategies for managing patients with PD and led to the development of dopamine replacement treatment using dopamine agonists (e.g., L-DOPA, ropinirole) and neuroprotective treatment (e.g., treatment with monoamine oxidase-B (MAO-B) inhibitors, glutamate antagonists, anti-apoptotic agents, growth factors) (Jenner 2004; Schapira 2009; Whone et al. 2003). Emerging evidence reveals that although dopaminergic treatment might provide some initial benefit in patients with PD, frequently

lose antiparkinsonian efficacy, and develop levodopa-related motor complications and psychiatric manifestations, which means that many patients ultimately develop both motor and nonmotor problems (Parati et al. 1993; Schapira 2009). Recent knowledge offers cell replacement as a potential therapeutic opportunity for restoring striatal dopaminergic function in both familial and sporadic PD. It has been reported that Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) may serve as promising sources of cells for transplantation in the striatum of PD patients (Björklund et al. 2002; Cai et al. 2009; Takahashi and Yamanaka 2006). Despite the fact that cell replacement studies have provided evidence for restoring motor functions in animal models of PD, to date, cell therapy efforts in PD patients have failed to show substantial clinical improvement and in some cases were hampered by the development of graft-induced dyskinesias (Cai et al. 2009; Politis et al. 2011). In addition, there is a considerable risk that they can overgrow and form teratoma after transplantation (Brederlau et al. 2006). More recently, gene therapy based on the adeno-associated viral vector (AAV)-mediated delivery of neuroprotective agents to the basal ganglia nuclei has provided a possible alternative approach to the conventional pharmacological treatments. It is now known that these gene therapy-based approaches failed in improving the motor symptoms in clinical trials and doubts about its benefits compared with existing drug treatment (Gasmi et al. 2007; Kaplitt et al. 2007; Lim et al. 2010). However, beyond these obstacles, currently, there is a general agreement that continued success in identifying the new genes implicated in the pathogenesis of PD is the best possible way to figure out what goes wrong at the molecular level and to use this knowledge to designing etiologic treatments for this complex disorder. In fact, it is clearly hoped that greater understanding of the genetic basis in inherited PD coupled with advancements in viral-mediated gene delivery may lead to potential gene replacement therapies and genetic defect corrections within the basal ganglia (etiologic gene therapy approach) (Büning et al. 2008; Singleton et al. 2013). In this context, several recent studies reported successful preclinical trials in multiple animal models based on the AAV-mediated delivery of *PARKIN* gene to the basal ganglia nuclei which reduced dopaminergic neurons degeneration and recovered motor functions (Manfredsson et al. 2007). Based on these findings, now, there is an incentive to broaden AAV-mediated gene replacement trials to other genetic defects associated with dopaminergic neuron degeneration, with this promising perspective that patients with different genetic defects may potentially benefit from gene replacement therapy in the future. Moreover, there is a common notion that understanding the potential mechanistic implications of these genes will broaden our options to design and produce

efficient and specific drugs that appropriately intervene with the pathobiological process in both familial and sporadic PD (Singleton et al. 2013).

Additionally, with the advent of high-throughput genetic analysis techniques and the access to large patient samples, biomedical researches in the field of Parkinsonism have been radically changed. More recently, genome-wide association studies (GWASs) have been combined with meta-analysis and together have identified over 12 genetic risk factors. Ongoing researches demonstrated that these loci may be associated with increased risk for PD by affecting expression levels or splicing process of the biologically relevant transcripts (Consortium 2011; Simon-Sanchez et al. 2009). Currently, there is an assumption that identifying pathobiologically relevant transcripts within these risk loci and subsequently modulating their expression levels may provide novel potential therapeutic approaches for treating PD (Singleton et al. 2003). Also, aside from therapeutic interventions, it is worth mentioning that rapid progress in identifying the genes implicated either in the familial PD or in the sporadic PD as risk factors will be useful for diagnosing the disease in affected persons at an early stage and providing an opportunity to initiate appropriate therapeutic interventions at a presymptomatic stage in which a significant proportion of dopaminergic neurons are still alive and treatment is most likely to succeed. Moreover, considering the relationship between genetic variations within the risk loci and the level of gene expressions, it seems logical that genetic profiling of individuals affected with sporadic forms of the disease and also identifying the causative gene in patients affected with familial forms of the disease will be important in categorizing patients based on the pathogenicity mechanism and adopting appropriate treatment as well as the determining the drug dosage for treatments (Gibbs et al. 2010; Singleton et al. 2013).

Overall, given the genetically heterogeneous nature of the PD, elucidation of the genetic architecture of sporadic and familial PD improves diagnostic accuracy rates (sensitivity and specificity) and consequently enables presymptomatic diagnosis of the at-risk individuals as well as prenatal testing in the affected families. Moreover, it expands our knowledge of the disease genetic and neuropathologic mechanisms which can be of major importance for the development of disease-modifying therapeutic strategies. Ultimately, it enhances our ability to categorize various PD patients into genetic subtypes. This classification of patients based on the genetic etiology and underlying molecular mechanisms can pave the way for the efficient treatment of the patients through the effective intervention (slowing or halting) in the disease process.

Author Contributions AKM conceived the project, performed critical analysis of current topics, and wrote the manuscript. SC advised

the conceptual ideas and provided critical feedback on the early draft. BB contributed to the final revision of the manuscript content. MRJ supervised the project and took the lead in overall direction and planning of the project. All authors discussed the results and contributed to the final manuscript.

Compliance with Ethical Standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW (2003) The role of pathogenic DJ-1 mutations in Parkinson's disease. *Ann Neurol* 54(3):283–286
- Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S et al (2009) Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. *Arch Neurol* 66(12):1517–1522
- Al-Din A, Wriekat A, Mubaidin A, Dasouki M, Hiari M (1994) Pallidopyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. *Acta Neurol Scand* 89(5):347–352
- Ali IK, McKendrick L, Morley SJ, Jackson RJ (2001) Truncated initiation factor eIF4G lacking an eIF4E binding site can support capped mRNA translation. *EMBO J* 20(15):4233–4242
- Al-Ramahi I, Pérez AM, Lim J, Zhang M, Sorensen R, De Haro M et al (2007) dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1. *PLoS Genet* 3(12):e234
- Annesi G, Savettieri G, Pugliese P, D'Amelio M, Tarantino P, Ragonese P et al (2005) DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex. *Ann Neurol* 58(5):803–807
- Appel-Cresswell S, Rajput AH, Sossi V, Thompson C, Silva V, McKenzie J et al (2014) Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S parkinsonism. *Mov Disord* 29:1684–1687
- Aras S, Pak O, Sommer N, Finley JrR, Hüttemann M, Weissmann N et al (2013) Oxygen-dependent expression of cytochrome c oxidase subunit 4–2 gene expression is mediated by transcription factors RBPJ, CXXC5 and CHCHD2. *Nucleic Acids Res* 41(4):2255–2266
- Aras S, Bai M, Lee I, Springett R, Hüttemann M, Grossman LI (2015) MNRR1 (formerly CHCHD2) is a bi-organellar regulator of mitochondrial metabolism. *Mitochondrion* 20:43–51
- Balsinde J, Balboa MA (2005) Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A 2 in activated cells. *Cell Signal* 17(9):1052–1062
- Bandopadhyay R, Kingsbury AE, Cookson MR, Reid AR, Evans IM, Hope AD et al (2004) The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. *Brain* 127(2):420–430
- Beck G, Shinzawa K, Hayakawa H, Baba K, Yasuda T, Sumi-Akamaru H et al (2015) Deficiency of calcium-independent phospholipase

- A2 Beta induces brain iron accumulation through upregulation of divalent metal transporter 1. *PLoS ONE* 10(10):e0141629
- Beck G, Shinzawa K, Hayakawa H, Baba K, Sumi-Akamaru H, Tsujimoto Y et al (2016) Progressive axonal degeneration of nigrostriatal dopaminergic neurons in calcium-independent phospholipase A2 β knockout mice. *PLoS ONE* 11(4):e0153789
- Berg D, Marek K, Ross GW, Poewe W (2012) Defining at-risk populations for Parkinson's disease: Lessons from ongoing studies. *Mov Disord* 27(5):656–665
- Björklund LM, Sánchez-Pernaute R, Chung S, Andersson T, Chen IYC, McNaught KSP et al (2002) Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. *Proc Natl Acad Sci USA* 99(4):2344–2349
- Bogaerts V, Nuytemans K, Reumers J, Pals P, Engelborghs S, Pickut B et al (2008) Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease. *Hum Mutat* 29(6):832–840
- Boldogh IR, Pon LA (2007) Mitochondria on the move. *Trends Cell Biol* 17(10):502–510
- Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E et al (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science* 299(5604):256–259
- Bras J, Simón-Sánchez J, Federoff M, Morgadinho A, Januario C, Ribeiro M et al (2008) Lack of replication of association between GIGYF2 variants and Parkinson disease. *Hum Mol Genet* 18(2):341–346
- Brederlau A, Correia AS, Anisimov SV, Elmi M, Paul G, Roybon L et al (2006) Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. *Stem Cells* 24(6):1433–1440
- Brieger K, Schiavone S, Miller FJ Jr, Krause KH (2012) Reactive oxygen species: from health to disease. *Swiss Med Wkly* 142:w13659
- Bugaric A, Zhe Y, Kerr MC, Griffin J, Collins BM, Teasdale RD (2011) Vps26A and Vps26B subunits define distinct retromer complexes. *Traffic* 12(12):1759–1773
- Büning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M (2008) Recent developments in adeno-associated virus vector technology. *J Gene Med* 10(7):717–733
- Burchell VS, Nelson DE, Sanchez-Martinez A, Delgado-Camprubi M, Ivatt RM, Pogson JH et al (2013) The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy. *Nat Neurosci* 16(9):1257–1265
- Burman JL, Yu S, Poole AC, Decal RB, Pallanck L (2012) Analysis of neural subtypes reveals selective mitochondrial dysfunction in dopaminergic neurons from parkin mutants. *Proc Natl Acad Sci USA* 109(26):10438–10443
- Cai J, Yang M, Poremsky E, Kidd S, Schneider JS, Iacovitti L (2009) Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. *Stem Cells Dev* 19(7):1017–1023
- Canet-Avilés RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S et al (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. *Proc Natl Acad Sci USA* 101(24):9103–9108
- Cao M, Wu YM, Ashrafi G, McCartney AJ, Wheeler H, Bushong EA et al (2017) Parkinson Sac domain mutation in synaptojanin 1 impairs clathrin uncoating at synapses and triggers dystrophic changes in dopaminergic axons. *Neuron* 93:882–896
- Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL et al (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. *J Neurosci* 27(30):8138–8148
- Chan NC, Salazar AM, Pham AH, Sweredoski MJ, Kolawa NJ, Graham RL et al (2011) Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. *Hum Mol Genet* ddr048
- Chartier-Harlin MC, Dachsel JC, Vilarinho-Güell C, Lincoln SJ, Lepêtre F, Hulihan MM et al (2011) Translation initiator EIF4G1 mutations in familial Parkinson disease. *Am J Hum Genet* 89(3):398–406
- Chen Y, Dorn GW (2013) PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. *Science* 340(6131):471–475
- Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC (2003) Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. *J Cell Biol* 160(2):189–200
- Choi J, Sullards MC, Olzmann JA, Rees HD, Weintraub ST, Bostwick DE et al (2006) Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. *J Biol Chem* 281(16):10816–10824
- Choy RWY, Cheng Z, Schekman R (2012) Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid β (A β) production in the trans-Golgi network. *Proc Natl Acad Sci USA* 109(30):E2077–E2082
- Cilenti L, Ambivero CT, Ward N, Alnemri ES, Germain D, Zervos AS (2014) Inactivation of Omi/HtrA2 protease leads to the deregulation of mitochondrial Mulan E3 ubiquitin ligase and increased mitophagy. *BBA-Mol Cell Res* 1843(7):1295–1307
- Clements CM, McNally RS, Conti BJ, Mak TW, Ting JPY (2006) DJ-1, a cancer-and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. *Proc Natl Acad Sci USA* 103(41):15091–15096
- Conedera S, Apaydin H, Li Y, Yoshino H, Ikeda A, Matsushima T et al (2016) FBXO7 mutations in Parkinson's disease and multiple system atrophy. *Neurobiol Aging* 40:e191–e195
- Consortium IPDG. (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet* 377(9766):641–649
- Cook C, Stetler C, Petrucelli L (2012) Disruption of protein quality control in Parkinson's disease. *Cold Spring Harb Perspect Med* 2(5):a009423
- Crosiers D, Ceulemans B, Meeus B, Nuytemans K, Pals P, Van Broeckhoven C et al (2011) Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation. *Parkinsonism Relat Disord* 17(2):135–138
- Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant α -synuclein by chaperone-mediated autophagy. *Science* 305(5688):1292–1295
- Damiano M, Gautier CA, Bulteau AL, Ferrando-Miguel R, Gouarne C, Paoli MG et al (2014) Tissue- and cell-specific mitochondrial defect in Parkin-deficient mice. *PLoS ONE* 9(6):e99898
- Davie CA (2008) A review of Parkinson's disease. *Br Med Bull* 86(1):109–127
- De Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. *Lancet Neurol* 5(6):525–535
- Deas E, Plun-Favreau H, Wood NW (2009) PINK1 function in health and disease. *EMBO Mol Med* 1(3):152–165
- Dehay B, Ramirez A, Martinez-Vicente M, Perier C, Canron MH, Doudnikoff E et al (2012) Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. *Proc Natl Acad Sci USA* 109(24):9611–9616
- DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M et al (2002) PARK3 influences age at onset in Parkinson

- disease: a genome scan in the GenePD study. *Am J Hum Genet* 70(5):1089–1095
- Dey B, Frick K, Lopaczynski W, Nissley S, Furlanetto R (1996) Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, Shc, and Grb10. *Mol Endocrinol* 10(6):631–641
- Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F et al (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. *Lancet* 365(9457):412–415
- Di Fonzo A, Dekker M, Montagna P, Baruzzi A, Yonova E, Guedes LC et al (2009a) FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. *Neurology* 72(3):240–245
- Di Fonzo A, Fabrizio E, Thomas A, Fincati E, Marconi R, Tinazzi M et al (2009b) GIGYF2 mutations are not a frequent cause of familial Parkinson's disease. *Parkinsonism Relat Disord* 15(9):703–705
- Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM et al (2009) Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. *Lancet Neurol* 8(12):1150–1157
- Dufresne AM, Smith RJ (2005) The adapter protein GRB10 is an endogenous negative regulator of insulin-like growth factor signaling. *Endocrinology* 146(10):4399–4409
- Edvardson S, Cinnamon Y, Ta-Shma A, Shaag A, Yim YI, Zenvirt S et al (2012) A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. *PLoS ONE* 7(5):e36458
- Evangelou E, Maraganore DM, Ioannidis JP (2007) Meta-analysis in genome-wide association datasets: strategies and application in Parkinson disease. *PLoS ONE* 2(2):e196
- Fan J, Ren H, Jia N, Fei E, Zhou T, Jiang P et al (2008a) DJ-1 decreases Bax expression through repressing p53 transcriptional activity. *J Biol Chem* 283(7):4022–4030
- Fan J, Ren H, Fei E, Jia N, Ying Z, Jiang P et al (2008b) Sumoylation is critical for DJ-1 to repress p53 transcriptional activity. *FEBS Lett* 582(7):1151–1156
- Follett J, Norwood SJ, Hamilton NA, Mohan M, Kovtun O, Tay S et al (2014) The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer. *Traffic* 15(2):230–244
- Franco-Iborra S, Vila M, Perier C (2016) The Parkinson disease mitochondrial hypothesis: where are we at? *Neuroscientist* 22(3):266–277
- Frederick RL, Shaw JM (2007) Moving mitochondria: establishing distribution of an essential organelle. *Traffic* 8(12):1668–1675
- Fukushima T, Tan X, Luo Y, Kanda H (2011) Serum vitamins and heavy metals in blood and urine, and the correlations among them in Parkinson's disease patients in China. *Neuroepidemiology* 36(4):240–244
- Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H et al (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. *Ann Neurol* 57(6):918–921
- Funayama M, Ohe K, Amo T, Furuya N, Yamaguchi J, Saiki S et al (2015) CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. *Lancet Neurol* 14(3):274–282
- Fuse A, Furuya N, Kakuta S, Inose A, Sato M, Koike M et al (2015) VPS29–VPS35 intermediate of retromer is stable and may be involved in the retromer complex assembly process. *FEBS Lett* 589(13):1430–1436
- Gao F, Chen D, Si J, Hu Q, Qin Z, Fang M et al (2015) The mitochondrial protein BNIP3L is the substrate of PARK2 and mediates mitophagy in PINK1/PARK2 pathway. *Hum Mol Genet* 24(9):2528–2538
- Gasmi M, Brandon EP, Herzog CD, Wilson A, Bishop KM, Hofer EK et al (2007) AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. *Neurobiol Dis* 27(1):67–76
- Gautier CA, Kitada T, Shen J (2008) Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. *Proc Natl Acad Sci USA* 105(32):11364–11369
- Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AH, Taanman JW (2010) Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. *Hum Mol Genet* 19(24):4861–4870
- Geisler S, Holmström KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ et al (2010) PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. *Nat Cell Biol* 12(2):119–131
- Gibbs JR, van der Brug MP, Hernandez DG, Traynor BJ, Nalls MA, Lai SL et al (2010) Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. *PLoS Genet* 6(5):e1000952
- Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ et al (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. *Lancet* 365(9457):415–416
- Giovannone B, Lee E, Laviola L, Giorgino F, Cleveland KA, Smith RJ (2003) Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling. *J Biol Chem* 278(34):31564–31573
- Giovannone B, Tsiaras WG, de la Monte S, Klysik J, Lautier C, Karashchuk G et al (2009) GIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signaling. *Hum Mol Genet* 18(23):4629–4639
- Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ et al (2009) α -Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. *Nat Genet* 41(3):308–315
- Goker-Alpan O, Schiffmann R, LaMarca M, Nussbaum R, McInerney-Leo A, Sidransky E (2004) Parkinsonism among Gaucher disease carriers. *J Med Genet* 41(12):937–940
- Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher's disease. *Lancet* 372(9645):1263–1271
- Greene AW, Grenier K, Aguilera MA, Muise S, Farazifard R, Haque ME et al (2012) Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. *EMBO Rep* 13(4):378–385
- Grünwald A, Arns B, Seibler P, Rakovic A, Münchau A, Ramirez A et al (2012) ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. *Neurobiol Aging* 33(8):e1841–e1847
- Guilarte TR (2010) Manganese and Parkinson's disease: a critical review and new findings. *Environ Health Perspect* 118(8):1071
- Guo Y, Jankovic J, Zhu S, Le W, Song Z, Xie W et al (2009) GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients. *Neurosci Lett* 454(3):209–211
- Gusdon AM, Zhu J, Van Houten B, Chu CT (2012) ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. *Neurobiol Dis* 45(3):962–972
- Gustavsson EK, Trinh J, Guella I, Vilarino-Guell C, Appel-Cresswell S, Stoessl AJ et al (2015) DNAJC13 genetic variants in parkinsonism. *Mov Disord* 30:273–278
- Gwinn-Hardy K, Chen J, Liu HC, Liu T, Boss M, Seltzer W et al (2000) Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. *Neurology* 55(6):800–805
- Halbach MV, Stehning T, Dammrath E, Jendrach M, Şen NE, Başak AN et al (2015) Both ubiquitin ligases FBXW8 and PARK2 are sequestered into insolubility by ATXN2 PolyQ expansions, but only FBXW8 expression is dysregulated. *PLoS One* 10(3):e0121089

- Hansen H, Svensson U, Zhu J, Laviola L, Giorgino F, Wolf G et al (1996) Interaction between the Grb10 SH2 domain and the insulin receptor carboxyl terminus. *J Biol Chem* 271(15):8882–8886
- Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C (2009) The genetics of Parkinson's syndromes: a critical review. *Curr Opin Genet Dev* 19(3):254–265
- Healy DG, Abou-Sleiman PM, Wood NW (2004) Genetic causes of Parkinson's disease: UCHL-1. *Cell Tissue Res* 318(1):189–194
- Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *Lancet Neurol* 7(7):583–590
- Heo JM, Ordureau A, Paulo JA, Rinehart J, Harper JW (2015) The PINK1-PARKIN mitochondrial ubiquitylation pathway drives a program of OPTN/NDP52 recruitment and TBK1 activation to promote mitophagy. *Mol Cell* 60(1):7–20
- Hernandez DG, Reed X, Singleton AB (2016) Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. *J Neurochem* 139(S1):59–74
- Hicks AA, Pétursson H, Jonsson T, Stefánsson H, Johannsdóttir HS, Sainz J et al (2002) A susceptibility gene for late-onset idiopathic Parkinson's disease. *Ann Neurol* 52(5):549–555
- Higashi S, Iseki E, Minegishi M, Togo T, Kabuta T, Wada K (2010) GIGYF2 is present in endosomal compartments in the mammalian brains and enhances IGF-1-induced ERK1/2 activation. *J Neurochem* 115(2):423–437
- Hofseth LJ, Hussain SP, Harris CC (2004) p53: 25 years after its discovery. *Trends Pharmacol Sci* 25(4):177–181
- Hozumi I, Hasegawa T, Honda A, Ozawa K, Hayashi Y, Hashimoto K et al (2011) Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. *J Neurol Sci* 303(1):95–99
- Hristova VA, Beasley SA, Rylett RJ, Shaw GS (2009) Identification of a novel Zn²⁺-binding domain in the autosomal recessive juvenile Parkinson-related E3 ligase parkin. *J Biol Chem* 284(22):14978–14986
- Ibáñez P, Lesage S, Lohmann E, Thobois S, Michele GD, Borg M et al (2006) Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. *Brain* 129(3):686–694
- Ibáñez P, Lesage S, Janin S, Lohmann E, Durif F, Destée A et al (2009) α -Synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. *Arch Neurol* 66(1):102–108
- Im JY, Lee KW, Woo JM, Junn E, Mouradian MM (2012) DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. *Hum Mol Genet* 21(13):3013–3024
- Ishikawa A, Tsuji S (1996) Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. *Neurology* 47(1):160–166
- Ishikawa S, Taira T, Niki T, Takahashi-Niki K, Maita C, Maita H et al (2009) Oxidative status of DJ-1-dependent activation of dopamine synthesis through interaction of tyrosine hydroxylase and 4-dihydroxy-L-phenylalanine (L-DOPA) decarboxylase with DJ-1. *J Biol Chem* 284(42):28832–28844
- Ishikawa S, Taira T, Takahashi-Niki K, Niki T, Ariga H, Iguchi-Ariga SM (2010) Human DJ-1-specific transcriptional activation of tyrosine hydroxylase gene. *J Biol Chem* 285(51):39718–39731
- Ishikawa S, Tanaka Y, Takahashi-Niki K, Niki T, Ariga H, Iguchi-Ariga SM (2012) Stimulation of vesicular monoamine transporter 2 activity by DJ-1 in SH-SY5Y cells. *Biochem Biophys Res Commun* 421(4):813–818
- Itoh K, Nakamura K, Iijima M, Sesaki H (2013) Mitochondrial dynamics in neurodegeneration. *Trends Cell Biol* 23(2):64–71
- Jankovic J (2008) Parkinson's disease: clinical features and diagnosis. *J Neurol Neurosurg Psychiatr* 79(4):368–376
- Jenner P (2003) Oxidative stress in Parkinson's disease. *Ann Neurol* 53:S3
- Jenner P (2004) Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. *Neurology* 63(7 suppl 2):S13–S22
- Jiménez-Jiménez FJ, Fernández-Calle P, Martínez-Vanaclocha M, Herrero E, Molina JA, Vázquez A et al (1992) Serum levels of zinc and copper in patients with Parkinson's disease. *J Neurol Sci* 112(1):30–33
- Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP, Youle RJ (2010) Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. *J Cell Biol* 191(5):933–942
- Jones JM, Datta P, Srinivasula SM, Ji W, Gupta S, Zhang Z et al (2003) Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. *Nature* 425(6959):721–727
- Junn E, Jang WH, Zhao X, Jeong BS, Mouradian MM (2009) Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. *J Neurosci Res* 87(1):123–129
- Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T (2004) LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. *J Cell Sci* 117(13):2805–2812
- Kalinderi K, Bostantjopoulou S, Fidani L (2016) The genetic background of Parkinson's disease: current progress and future prospects. *Acta Neurol Scand* 134(5):314–326
- Kane LA, Lazarou M, Fogel AI, Li Y, Yamano K, Sarraf SA et al (2014) PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. *J Cell Biol* JCB 201402104
- Kang S, Louboutin J, Datta P, Landel C, Martinez D, Zervos A et al (2013) Loss of HtrA2/Omi activity in non-neuronal tissues of adult mice causes premature aging. *Cell Death Differ* 20(2):259–269
- Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA et al (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. *Lancet* 369(9579):2097–2105
- Kato I, Maita H, Takahashi-Niki K, Saito Y, Noguuchi N, Iguchi-Ariga SM et al (2013) Oxidized DJ-1 inhibits p53 by sequestering p53 from promoters in a DNA-binding affinity-dependent manner. *Mol Cell Biol* 33(2):340–359
- Kauther KM, Höft C, Rissling I, Oertel WH, Möller JC (2011) The PLA2G6 gene in early-onset Parkinson's disease. *Mov Disord* 26(13):2415–2417
- Kazlauskaite A, Kondapalli C, Gurlay R, Campbell DG, Ritorito MS, Hofmann K et al (2014) Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. *Biochem J* 460(1):127–141
- Keller MF, Saad M, Bras J, Bettella F, Nicolaou N, Simón-Sánchez J et al (2012) Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. *Hum Mol Genet* 21(22):4996–5009
- Kempster PA, Hurwitz B, Lees AJ (2007) A new look at James Parkinson's essay on the shaking palsy. *Neurology* 69(5):482–485
- Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. *Annu Rev Pharmacol Toxicol* 47:89–116
- Kieper N, Holmström KM, Ciceri D, Fiesel FC, Wolburg H, Ziviani E et al (2010) Modulation of mitochondrial function and morphology by interaction of Omi/HtrA2 with the mitochondrial fusion factor OPA1. *Exp Cell Res* 316(7):1213–1224
- Kim SJ, Park YJ, Hwang IY, Youdim MB, Park KS, Oh YJ (2012) Nuclear translocation of DJ-1 during oxidative stress-induced neuronal cell death. *Free Radic Biol Med* 53(4):936–950
- Kinumi T, Kimata J, Taira T, Ariga H, Niki E (2004) Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. *Biochem Biophys Res Commun* 317(3):722–728

- Klein C, Hedrich K, Wellenbrock C, Kann M, Harris J, Marder K et al (2003) Frequency of parkin mutations in late-onset Parkinson's disease. *Ann Neurol* 54(3):415–416
- Kojovic M, Sheerin UM, Rubio-Agusti I, Saha A, Bras J, Gibbons V et al (2012) Young-onset parkinsonism due to homozygous duplication of α -synuclein in a consanguineous family. *Mov Disord* 27(14):1829–1830
- Kondapalli C, Kazlauskaitė A, Zhang N, Woodroof HI, Campbell DG, Gourlay R et al (2012) PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. *Open Biol* 2(5):120080
- Kong SM, Chan BK, Park JS, Hill KJ, Aitken JB, Cottle L et al (2014) Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α -Synuclein externalization via exosomes. *Hum Mol Genet* 23(11):2816–2833
- Kono S, Shirakawa K, Ouchi Y, Sakamoto M, Ida H, Sugiura T et al (2007) Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier. *J Neurol Sci* 252(2):181–184
- Kononenko NL, Haucke V (2015) Molecular mechanisms of pre-synaptic membrane retrieval and synaptic vesicle reformation. *Neuron* 85:484–496
- Koroglu C, Baysal L, Cetinkaya M, Karasoy H, Tolun A (2013) DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. *Parkinsonism Relat Disord* 19:320–324
- Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M et al (2014) Ubiquitin is phosphorylated by PINK1 to activate parkin. *Nature* 510(7503):162–166
- Krebs CE, Karkheiran S, Powell JC, Cao M, Makarov V, Darvish H et al (2013) The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive parkinsonism with generalized seizures. *Hum Mutat* 34:1200–1207
- Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES (1996) Parametric and nonparametric linkage analysis: a unified multipoint approach. *Am J Hum Genet* 58(6):1347
- Kumar KR, Weissbach A, Heldmann M, Kasten M, Tunc S, Sue CM et al (2012) Frequency of the D620N mutation in VPS35 in Parkinson disease. *Arch Neurol* 69(10):1360–1364
- Lander E, Kruglyak L (1995) Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. *Nat Genet* 11(3):241–247
- Langlais P, Dong LQ, Ramos FJ, Hu D, Li Y, Quon MJ et al (2004) Negative regulation of insulin-stimulated mitogen-activated protein kinase signaling by Grb10. *Mol Endocrinol* 18(2):350–358
- Laurent-Matha V, Derocq D, Prébois C, Katunuma N, Liaudet-Coopman E (2006) Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B. *J Biochem* 139(3):363–371
- Lautier C, Goldwurm S, Dürr A, Giovannone B, Tsiras WG, Pezzoli G et al (2008) Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. *Am J Hum Genet* 82(4):822–833
- Lazarou M, Jin SM, Kane LA, Youle RJ (2012) Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin. *Dev Cell* 22(2):320–333
- Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E et al (1998) The ubiquitin pathway in Parkinson's disease. *Nature* 395(6701):451–452
- Lesage S, Brice A (2009) Parkinson's disease: from monogenic forms to genetic susceptibility factors. *Hum Mol Genet* 18(1):48–59
- Lesage S, Anheim M, Letournel F, Bousset L, Honoré A, Rozas N et al (2013) G51D α -synuclein mutation causes a novel Parkinsonian-pyramidal syndrome. *Ann Neurol* 73(4):459–471
- Lesage S, Drouet V, Majounie E, Deramecourt V, Jacoupy M, Nicolas A et al (2016) Loss of VPS13C function in autosomal-recessive parkinsonism causes mitochondrial dysfunction and increases PINK1/Parkin-dependent mitophagy. *Am J Hum Genet* 98(3):500–513
- Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BMM et al (2012) Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. *PLoS Genet* 8(3):e1002548
- Lim ST, Airavaara M, Harvey BK (2010) Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. *Pharmacol Res* 61(1):14–26
- Lin MK, Farrer MJ (2014) Genetics and genomics of Parkinson's disease. *Genome Med* 6(6):48
- Lin L, Ozaki T, Takada Y, Kageyama H, Nakamura Y, Hata A et al (2005) Topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage. *Oncogene* 24(21):3385–3396
- Lin CH, Chen ML, Chen GS, Tai CH, Wu RM (2011) Novel variant Pro143Ala in HTRA2 contributes to Parkinson's disease by inducing hyperphosphorylation of HTRA2 protein in mitochondria. *Hum Genet* 130(6):817–827
- Liu S, Ninan I, Antonova I, Battaglia F, Trinchese F, Narasanna A et al (2004) α -Synuclein produces a long-lasting increase in neurotransmitter release. *EMBO J* 23(22):4506–4516
- Liu S, Sawada T, Lee S, Yu W, Silverio G, Alapatt P et al (2012a) Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. *PLoS Genet* 8(3):e1002537
- Liu L, Feng D, Chen G, Chen M, Zheng Q, Song P et al (2012b) Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. *Nat Cell Biol* 14(2):177–185
- Liu Y, Clegg H, Leslie P, Di J, Tollini L, He Y et al (2015) CHCHD2 inhibits apoptosis by interacting with Bcl-x L to regulate Bax activation. *Cell Death Differ* 22(6):1035
- Lohmann E, Periquet M, Bonifati V, Wood NW, De Michele G, Bonnet AM et al (2003) How much phenotypic variation can be attributed to parkin genotype? *Ann Neurol* 54(2):176–185
- Lohmann E, Thobois S, Lesage S, Broussolle E, du Montcel ST, Ribeiro MJ et al (2009) A multidisciplinary study of patients with early-onset PD with and without parkin mutations. *Neurology* 72(2):110–116
- Lotharius J, Brundin P (2002) Impaired dopamine storage resulting from α -synuclein mutations may contribute to the pathogenesis of Parkinson's disease. *Hum Mol Genet* 11(20):2395–2407
- Lu CS, Chou YHW, Kuo PC, Chang HC, Weng YH (2004) The parkinsonian phenotype of spinocerebellar ataxia type 2. *Arch Neurol* 61(1):35–38
- Lücking CB, Dürr A, Bonifati V, Vaughan J, De Michele G, Gasser T et al (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. *N Engl J Med* 342(21):1560–1567
- Mandel H, Saita S, Edvardson S, Jalas C, Shaag A, Goldsher D et al (2016) Deficiency of HTRA2/Omi is associated with infantile neurodegeneration and 3-methylglutaconic aciduria. *J Med Genet*. <https://doi.org/10.1136/jmedgenet-2016-103922>
- Manfredsson FP, Burger C, Sullivan LF, Muzyczka N, Lewin AS, Mandel RJ (2007) rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. *Exp Neurol* 207(2):289–301
- Maraganore DM, De Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Krüger R et al (2006) Collaborative analysis of α -synuclein gene promoter variability and Parkinson disease. *JAMA* 296(6):661–670

- Martinat C, Shendelman S, Jonason A, Leete T, Beal MF, Yang L et al (2004) Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES-derived cell model of primary parkinsonism. *PLoS Biol* 2(11):e327
- Martins LM, Morrison A, Klupsch K, Fedele V, Moiso N, Teismann P et al (2004) Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. *Mol Cell Biol* 24(22):9848–9862
- Mata IF, Lockhart PJ, Farrer MJ (2004) Parkin genetics: one model for Parkinson's disease. *Hum Mol Genet* 13:127–133
- Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA et al (2010) PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. *J Cell Biol* 189(2):211–221
- Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA et al (2011) Gaucher disease glucocerebrosidase and α -synuclein form a bidirectional pathogenic loop in synucleinopathies. *Cell* 146(1):37–52
- McLelland GL, Soubannier V, Chen CX, McBride HM, Fon EA (2014) Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. *EMBO J* 33(4):e201385902
- Meissner C, Lorenz H, Weihofen A, Selkoe DJ, Lemberg MK (2011) The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. *J Neurochem* 117(5):856–867
- Meray RK, Lansbury PT (2007) Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1. *J Biol Chem* 282(14):10567–10575
- Miura E, Hasegawa T, Konno M, Suzuki M, Sugeno N, Fujikake N et al (2014) VPS35 dysfunction impairs lysosomal degradation of α -synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease. *Neurobiol Dis* 71:1–13
- Moghadam AK, Vallian J, Vallian S (2017) Molecular characterization of A1PL1 gene region in the Iranian population: application of novel informative haplotypes and detection of mutational founder effect. *Genes Genom* 39(4):433–443
- Moiso N, Fedele V, Edwards J, Martins LM (2014) Loss of PINK1 enhances neurodegeneration in a mouse model of Parkinson's disease triggered by mitochondrial stress. *Neuropharmacology* 77:350–357
- Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S et al (2006) PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. *Nat Genet* 38(7):752–754
- Mullin S, Schapira A (2013) α -Synuclein and mitochondrial dysfunction in Parkinson's disease. *Mol Neurobiol* 47(2):587
- Murphy KE, Cottle L, Gysbers AM, Cooper AA, Halliday GM (2013) ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. *Acta Neuropathol Commun* 1(1):11
- Mutez E, Leprêtre F, Le Rhun E, Larvor L, Duflo A, Mouroux V et al (2011) SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. *Hum Mutat* 32(4)
- Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM et al (1997) DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. *Biochem Biophys Res Commun* 231(2):509–513
- Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M et al (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nat Genet* 46(9):989
- Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J et al (2010) PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. *PLoS Biol* 8(1):e1000298
- Narendra D, Walker JE, Youle R (2012) Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism. *Cold Spring Harb Perspect Biol* 4(11):a011338
- Nelson DE, Randle SJ, Laman H (2013) Beyond ubiquitination: the atypical functions of Fbxo7 and other F-box proteins. *Open Biol* 3(10):130131
- Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK et al (2010) Increased expression of α -synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. *Neuron* 65(1):66–79
- Nichols WC, Pankratz N, Hernandez D, Paisán-Ruiz C, Jain S, Halter CA et al (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. *Lancet* 365(9457):410–412
- Nishikawa K, Li H, Kawamura R, Osaka H, Wang YL, Hara Y et al (2003) Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. *Biochem Biophys Res Commun* 304(1):176–183
- Nkiliza A, Mutez E, Simonin C, Leprêtre F, Duflo A, Figeac M et al (2016) RNA-binding disturbances as a continuum from spinocerebellar ataxia type 2 to Parkinson disease. *Neurobiol Dis* 96:312–322
- Nowak DM, Pitarque JA, Molinari A, Bejjani BA, Gajecka M (2012) Linkage analysis as an approach for disease-related loci identification. *Comput Methods Sci Technol* 18:95–101
- Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. *Hum Mutat* 31(7):763–780
- O'sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ (2008) Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. *Mov Disord* 23(1):101–106
- Okatsu K, Uno M, Koyano F, Go E, Kimura M, Oka T et al (2013) A dimeric PINK1-containing complex on depolarized mitochondria stimulates Parkin recruitment. *J Biol Chem* 288(51):36372–36384
- Oláhová M, Thompson K, Hardy SA, Barbosa IA, Besse A, Anagnostou ME et al (2017) Pathogenic variants in HTRA2 cause an early-onset mitochondrial syndrome associated with 3-methylglutaconic aciduria. *J Inher Metab Dis* 40(1):121
- Olgati S, DE Rosa A, Quadri M, Criscuolo C, Breedveld GJ, Picillo M et al (2014) PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family. *Neurogenetics* 15:183–188
- Olgati S, Quadri M, Fang MY, Rood J, Saute JA, Chien HF et al (2016) DNAJC6 mutations associated with early-onset Parkinson's disease. *Ann Neurol* 79:244–256
- Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H et al (2003) Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. *Hum Mol Genet* 12(16):1945–1958
- Otsu K, Murakawa T, Yamaguchi O (2015) BCL2L13 is a mammalian homolog of the yeast mitophagy receptor Atg32. *Autophagy* 11(10):1932–1933
- Ott J, Wang J, Leal SM (2015) Genetic linkage analysis in the age of whole-genome sequencing. *Nat Rev Genet* 16(5):275–284
- Ottolini D, Cali T, Negro A, Brini M (2013) The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering. *Hum Mol Genet* 22(11):2152–2163
- Paisán-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW et al (2009) Characterization of PLA2G6 as a locus for dystonia-parkinsonism. *Ann Neurol* 65(1):19–23
- Paisán-Ruiz C, Guevara R, Federoff M, Hanagasi H, Sina F, Elahi E et al (2010) Early-onset L-dopa-responsive parkinsonism with

- pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatac-sin mutations. *Mov Disord* 25(12):1791–1800
- Pals P, Van Everbroeck B, Grubben B, Kristina Viaene M, Dom R, van der Linden C et al (2003) Case-control study of environmental risk factors for Parkinson's disease in Belgium. *Eur J Epidemiol* 18(12):1133–1142
- Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C et al (2002) Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. *Am J Hum Genet* 71(1):124–135
- Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A et al (2003) Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. *Hum Mol Genet* 12(20):2599–2608
- Pao KC, Stanley M, Han C, Lai YC, Murphy P, Balk K et al (2016) Probes of ubiquitin E3 ligases enable systematic dissection of parkin activation. *Nat Chem Biol* 12(5):324–331
- Parati E, Fetoni V, Geminiani G, Soliveri P, Giovannini P, Testa D et al (1993) Response to L-DOPA in multiple system atrophy. *Clin Neuropharmacol* 16(2):139–144
- Park J, Lee SB, Lee S, Kim Y, Song S, Kim S et al (2006) Mitochondrial dysfunction in *Drosophila* PINK1 mutants is complemented by parkin. *Nature* 441(7097):1157–1161
- Payami H, Nutt J, Gancher S, Bird T, McNeal MG, Seltzer WK et al (2003) SCA2 may present as levodopa-responsive parkinsonism. *Mov Disord* 18(4):425–429
- Periquet M, Latouche M, Lohmann E, Rawal N, De Michele G, Ricard S et al (2003) Parkin mutations are frequent in patients with isolated early-onset parkinsonism. *Brain* 126(6):1271–1278
- Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L et al (2002) Parkin protects against the toxicity associated with mutant α -synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. *Neuron* 36(6):1007–1019
- Pickrell AM, Youle RJ (2015) The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. *Neuron* 85(2):257–273
- Politis M, Oertel WH, Wu K, Quinn NP, Pogarell O, Brooks DJ et al (2011) Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. *Mov Disord* 26(11):1997–2003
- Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G et al (1996) Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. *Science* 274(5290):1197–1199
- Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al (1997) Mutation in the α -synuclein gene identified in families with Parkinson's disease. *Science* 276(5321):2045–2047
- Poole AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, Pallanck LJ (2008) The PINK1/Parkin pathway regulates mitochondrial morphology. *Proc Natl Acad Sci USA* 105(5):1638–1643
- Poole AC, Thomas RE, Yu S, Vincow ES, Pallanck L (2010) The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway. *PLoS ONE* 5(4):e10054
- Quadri M, Fang MY, Picillo M, Olgiati S, Breedveld GJ, Graafland J et al (2013) Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset parkinsonism. *Hum Mutat* 34:1208–1215
- Ragothaman M, Sarangmath N, Chaudhary S, Khare V, Mittal U, Sharma S et al (2004) Complex phenotypes in an Indian family with homozygous SCA2 mutations. *Ann Neurol* 55(1):130–133
- Ramirez A, Heimbach A, Gründemann J, Stiller B, Hampshire D, Cid LP et al (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. *Nat Genet* 38(10):1184–1191
- Ramírez-Valle F, Braunstein S, Zavadil J, Formenti SC, Schneider RJ (2008) eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. *J Cell Biol* 181(2):293–307
- Randle J, Laman S H (2017) Structure and function of Fbxo7/PARK15 in Parkinson's disease. *Curr Protein Pept Sci* 18(7):715–724
- Rathke-Hartlieb S, Schloman U, Heimann P, Meisler MH, Jockusch H, Bartsch JW (2002) Progressive loss of striatal neurons causes motor dysfunction in MND2 mutant mice and is not prevented by Bcl-2. *Exp Neurol* 175(1):87–97
- Rentschler G, Covolo L, Haddad AA, Lucchini RG, Zoni S, Broberg K (2012) ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganese. *Neurotoxicology* 33(4):697–702
- Ross JP, Dupre N, Dauvilliers Y, Strong S, Ambalavanan A, Spiegelman D et al (2016) Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease. *Neurobiol Aging* 45:e13–e17
- Ryan BJ, Hoek S, Fon EA, Wade-Martins R (2015) Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. *Trends Biochem Sci* 40(4):200–210
- Saez-Atienzar S, Bonet-Ponce L, Blesa J, Romero F, Murphy M, Jordan J et al (2014) The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling. *Cell Death Dis* 5(8):e1368
- Saigoh K, Wang YL, Suh JG, Yamanishi T, Sakai Y, Kiyosawa H et al (1999) Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in *gad* mice. *Nat Genet* 23(1):47–51
- Sarraf SA, Raman M, Guarani-Pereira V, Sowa ME, Huttlin EL, Gygi SP et al (2013) Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. *Nature* 496(7445):372–376
- Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M et al (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. *Nat Genet* 41(12):1303–1307
- Satterfield TF, Pallanck LJ (2006) Ataxin-2 and its *Drosophila* homolog, ATX2, physically assemble with polyribosomes. *Hum Mol Genet* 15(16):2523–2532
- Schapira AH (2009) Neurobiology and treatment of Parkinson's disease. *Trend Pharmacol Sci* 30(1):41–47
- Schapira AH, Jenner P (2011) Etiology and pathogenesis of Parkinson's disease. *Mov Disord* 26(6):1049–1055
- Schapira AH, Olanow CW, Greenamyre JT, Bezdard E (2014) Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. *Lancet* 384(9942):545–555
- Schneider RJ, Sonenberg N (2007) Translational control in cancer development and progression. *Cold Spring Harbor Monogr Ser* 48:401
- Schrag A, Ben-Shlomo Y, Quinn N (2000) Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London. *BMJ* 321(7252):21–22
- Schregermann SR, Houlden H (2016) VPS13C—another hint at mitochondrial dysfunction in familial Parkinson's disease. *Mov Disord* 31(9):1340–1340
- Seaman MN (2007) Identification of a novel conserved sorting motif required for retromer-mediated endosome-to-TGN retrieval. *J Cell Sci* 120(14):2378–2389
- Segura-Aguilar J, Paris I, Muñoz P, Ferrari E, Zecca L, Zucca FA (2014) Protective and toxic roles of dopamine in Parkinson's disease. *J Neurochem* 129(6):898–915
- Shen Q, Yamano K, Head BP, Kawajiri S, Cheung JT, Wang C et al (2014) Mutations in Fis1 disrupt orderly disposal of defective mitochondria. *Mol Biol Cell* 25(1):145–159
- Shimura H, Hattori N, Kubo SI, Mizuno Y, Asakawa S, Minoshima S et al (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. *Nat Genet* 25(3):302–305

- Shinzawa K, Sumi H, Ikawa M, Matsuoka Y, Okabe M, Sakoda S et al (2008) Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease. *J Neurosci* 28(9):2212–2220
- Shiura H, Miyoshi N, Konishi A, Wakisaka-Saito N, Suzuki R, Mugiuruma K et al (2005) *Meg1/Grb10* overexpression causes postnatal growth retardation and insulin resistance via negative modulation of the IGF1R and IR cascades. *Biochem Biophys Res Commun* 329(3):909–916
- Shojaee S, Sina F, Banihosseini SS, Kazemi MH, Kalhor R, Shahidi GA et al (2008) Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. *Am J Hum Genet* 82(6):1375–1384
- Sidransky E (2004) Gaucher disease: complexity in a “simple” disorder. *Mol Genet Metab* 83(1):6–15
- Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J et al (2009) Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. *Nat Cell Biol* 11(7):903–908
- Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D et al (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. *Nat Genet* 41(12):1308–1312
- Simón-Sánchez J, Van Hilten JJ, Van De Warrenburg B, Post B, Berendse HW, Arepalli S et al (2011) Genome-wide association study confirms extant PD risk loci among the Dutch. *Eur J Hum Genet* 19(6):655–661
- Sina F, Shojaee S, Elahi E, Paisán-Ruiz C (2009) R632W mutation in *PLA2G6* segregates with dystonia-parkinsonism in a consanguineous Iranian family. *Eur J Neurol* 16(1):101–104
- Singleton A, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J et al (2003) α -Synuclein locus triplication causes Parkinson’s disease. *Science* 302(5646):841–841
- Singleton AB, Farrer MJ, Bonifati V (2013) The genetics of Parkinson’s disease: progress and therapeutic implications. *Mov Disord* 28(1):14–23
- Song Z, Chen H, Fiket M, Alexander C, Chan DC (2007) OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and Yme1L. *J Cell Biol* 178(5):749–755
- Stafa K, Tsika E, Moser R, Musso A, Glauser L, Jones A et al (2013) Functional interaction of Parkinson’s disease-associated *LRRK2* with members of the dynamin GTPase superfamily. *Hum Mol Genet* 23(8):2055–2077
- Stefanis L (2012) α -Synuclein in Parkinson’s disease. *Cold Spring Harb Perspect Med* 2(2):a009399
- Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S et al (2017) The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. *Hum Genet* 1–13
- Stern MB, Lang A, Poewe W (2012) Toward a redefinition of Parkinson’s disease. *Mov Disord* 27(1):54–60
- Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D et al (2005) Loss of function mutations in the gene encoding *Omi/HtrA2* in Parkinson’s disease. *Hum Mol Genet* 14(15):2099–2111
- Su YC, Qi X (2013) Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by *LRRK2 G2019S* mutation. *Hum Mol Genet* 22(22):4545–4561
- Sulzer D (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. *Trend Neurosci* 30(5):244–250
- Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, Takahashi R (2001) A serine protease, *HtrA2*, is released from the mitochondria and interacts with XIAP, inducing cell death. *Mol cell* 8(3):613–621
- Taccioli C, Maselli V, Tegnér J, Gomez-Cabrero D, Altobelli G, Emmett W et al (2011) ParkDB: a Parkinson’s disease gene expression database. Database 2011:bar007. <https://doi.org/10.1093/database/bar007>
- Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126(4):663–676
- Tan E, Schapira A (2010) Summary of GIGYF2 studies in Parkinson’s disease: the burden of proof. *Eur J Neurol* 17(2):175–176
- Tan J, Zhang T, Jiang L, Chi J, Hu D, Pan Q et al (2011) Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated *ATP13A2* protein. *J Biol Chem* 286(34):29654–29662
- Tanaka K, Suzuki T, Hattori N, Mizuno Y (2004) Ubiquitin, proteasome and parkin. *BBA-Mol Cell Res* 1695(1):235–247
- Thomas RE, Andrews LA, Burman JL, Lin WY, Pallanck LJ (2014) *PINK1*-Parkin pathway activity is regulated by degradation of *PINK1* in the mitochondrial matrix. *PLoS Genet* 10(5):e1004279
- Tofaris GK (2012) Lysosome-dependent pathways as a unifying theme in Parkinson’s disease. *Mov Disord* 27(11):1364–1369
- Trempe JF, Sauvé V, Grenier K, Seirafi M, Tang MY, Ménade M et al (2013) Structure of parkin reveals mechanisms for ubiquitin ligase activation. *Science* 340(6139):1451–1455
- Tsika E, Glauser L, Moser R, Fiser A, Daniel G, Sheerin UM et al (2014) Parkinson’s disease-linked mutations in *VPS35* induce dopaminergic neurodegeneration. *Hum Mol Genet* 23(12):4621–4638
- Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S et al (2004) Hereditary early-onset Parkinson’s disease caused by mutations in *PINK1*. *Science* 304(5674):1158–1160
- Vargas MR, Johnson JA (2009) The Nrf2–ARE cytoprotective pathway in astrocytes. *Expert Rev Mol Med* 11
- Vecchione A, Marchese A, Henry P, Rotin D, Morrione A (2003) The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor. *Mol Cell Biol* 23(9):3363–3372
- Velayati A, Yu WH, Sidransky E (2010) The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. *Curr Neurol Neurosci Rep* 10(3):190
- Velayos-Baeza A, Vettori A, Copley RR, Dobson-Stone C, Monaco A (2004) Analysis of the human *VPS13* gene family. *Genomics* 84(3):536–549
- Venderova K, Park DS (2012) Programmed cell death in Parkinson’s disease. *Cold Spring Harb Perspect Med* 2(8):a009365
- Verstraeten A, Theuns J, Van Broeckhoven C (2015) Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. *Trends Genet* 31(3):140–149
- Vilarino-Guell C, Rajput A, Milnerwood AJ, Shah B, Szu-Tu C, Trinh J et al (2014) DNAJC13 Mutations In Parkinson Disease. *Hum Mol Genet* 23:1794–1801
- Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ et al (2011) *VPS35* mutations in Parkinson disease. *Am J Hum Genet* 89(1):162–167
- Vingill S, Brockelt D, Lancelin C, Tatenhorst L, Dontcheva G, Preisinger C et al (2016) Loss of *FBXO7* (*PARK15*) results in reduced proteasome activity and models a parkinsonism-like phenotype in mice. *EMBO J* 35(18):2008–2025
- Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, Kim J et al (2010) *PINK1*-dependent recruitment of Parkin to mitochondria in mitophagy. *Proc Natl Acad Sci USA* 107(1):378–383
- Walle LV, Lamkanfi M, Vandenabeele P (2008) The mitochondrial serine protease *HtrA2/Omi*: an overview. *Cell Death Differ* 15(3):453–460
- Wang G, Mao Z (2014) Chaperone-mediated autophagy: roles in neurodegeneration. *Transl Neurodegener* 3(1):20

- Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D et al (2011) PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. *Cell* 147(4):893–906
- Wang X, Yan MH, Fujioka H, Liu J, Wilson-Delfosse A, Chen SG et al (2012) LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. *Hum Mol Genet* 21(9):1931–1944
- Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C et al (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. *Ann Neurol* 54(1):93–101
- Williams DR, Hadeed A, al-Din ASN, Wreikat AL, Lees AJ (2005) Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. *Mov Disord* 20(10):1264–1271
- Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S et al (2011) In vivo demonstration that α -synuclein oligomers are toxic. *Proc Natl Acad Sci USA* 108(10):4194–4199
- Wszolek ZK, Pfeiffer B, Fulgham J, Parisi JE, Thompson B, Uitti RJ et al (1995) Western Nebraska family (family D) with autosomal dominant parkinsonism. *Neurology* 45(3):502–505
- Xilouri M, Brekk OR, Stefanis L (2016) Autophagy and alpha-synuclein: relevance to Parkinson's disease and related synucleopathies. *Mov Disord* 31(2):178–192
- Xu J, Zhong N, Wang H, Elias JE, Kim CY, Woldman I et al (2005) The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. *Hum Mol Genet* 14(9):1231–1241
- Xu Y, Sun Y, Ran H, Quinn B, Witte D, Grabowski G (2011) Accumulation and distribution of α -synuclein and ubiquitin in the CNS of Gaucher disease mouse models. *Mol Genet Metab* 102(4):436–447
- Yamano K, Fogel AI, Wang C, van der Blik AM, Youle RJ (2014) Mitochondrial Rab GAPs govern autophagosome biogenesis during mitophagy. *Elife* 3:e01612
- Yang Z, Klionsky DJ (2010) Eaten alive: a history of macroautophagy. *Nat Cell Biol* 12(9):814–822
- Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C (2003) Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. *Genes Dev* 17(12):1487–1496
- Yoshida S, Hasegawa T, Suzuki M, Sugeno N, Kobayashi J, Ueyama M et al (2018) Parkinson's Disease-linked DNAJC13 mutation aggravates alpha-synuclein-induced neurotoxicity through perturbation of endosomal trafficking. *Hum Mol Genet* 27:823–836
- Yoshino H, Tomiyama H, Tachibana N, Ogaki K, Li Y, Funayama M et al (2010) Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. *Neurology* 75(15):1356–1361
- Youle RJ, Narendra DP (2011) Mechanisms of mitophagy. *Nat Rev Mol Cell Biol* 12(1):9–14
- Yu S, Zuo X, Li Y, Zhang C, Zhou M, Zhang YA et al (2004) Inhibition of tyrosine hydroxylase expression in α -synuclein-transfected dopaminergic neuronal cells. *Neurosci Lett* 367(1):34–39
- Yu T, Wang L, Yoon Y (2015) Morphological control of mitochondrial bioenergetics. *Front Biosci* 20:229
- Zabetian CP, Yamamoto M, Lopez AN, Ujike H, Mata IF, Izumi Y et al (2009) LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease. *Mov Disord* 24(7):1034–1041
- Zavodszky E, Seaman MN, Moreau K, Jimenez-Sanchez M, Breusegem SY, Harbour ME et al (2014) Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy. *Nat Commun* 5
- Zhang L, Shimoji M, Thomas B, Moore DJ, Yu SW, Marupudi NI et al (2005) Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. *Hum Mol Genet* 14(14):2063–2073
- Zhong N, Kim CY, Rizzu P, Geula C, Porter DR, Pothos EN et al (2006) DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. *J Biol Chem* 281(30):20940–20948
- Zhou W, Zhu M, Wilson MA, Petsko GA, Fink AL (2006) The oxidation state of DJ-1 regulates its chaperone activity toward α -synuclein. *J Mol Biol* 356(4):1036–1048
- Zhou ZD, Sathiyamoorthy S, Angeles DC, Tan EK (2016) Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson's disease (PD). *Mol Brain* 9(1):41
- Zucca FA, Basso E, Cupaioli FA, Ferrari E, Sulzer D, Casella L, Zecca L (2014) Neuromelanin of the human substantia nigra: an update. *Neurotox Res* 25(1):13–23